Executive summary

BACKGROUND

The French public health insurance system was implemented in 1945. It is divided into three main schemes, as shown here.

- The general scheme, which covers employees in the industry, business and services sectors, covers 85% of the French population. It is managed by the National Health Insurance Fund for Salaried Employees (Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, CNAMTS).

- The agricultural scheme, which covers farmers and farm employees (about 7% of the population covered), is managed by the Agricultural Mutual Insurance Fund (Mutualité Sociale Agricole, MSA).

- The scheme for non-salaried and non-farming, self-employed workers (about 5% of the population covered), which covers crafts people, retailers and independent professions, is managed by various organisations belonging to the National Insurance Fund for Self-employed Workers (Régime Social des Indépendants, RSI).

The system also includes a number of other special schemes (sailors, miners, railway employees, Paris public transport employees, employees from the Electricity and Gas Board, etc.). Their coverage is also based on a work-related basis.

The general health insurance scheme is funded mainly through:

- social contributions (46% of the funding) based on earnings from employees, employers and those on benefits (retired people, those on early retirement benefit and unemployed people) as a proportion of wages and salaries;

- taxes (45%);

- and other sources of funding: 9.1%, including state contribution and transfers.

In 2005, the total health expenditure (Dépenses totales de santé, THE) was 11% of gross domestic product (Produit intérieur brut, GDP), of which 80% was public expenditure and 20% was private expenditure. Private health insurance in France corresponds to complementary health insurance which patients subscribe to on a (usually) voluntary basis. A total of 93% of the population is covered by complementary health insurance, including 4% covered by the free Complementary Universal Health Insurance Coverage (CMUC), provided for people with low incomes.
**Figure 1: France - Main actors in the health care system**

**STATE**
- Defines health guidelines and conditions of financial balance
- Guarantees smooth running of the system

**HAUTE AUTORITE DE SANTE**
- Scientific evaluation
- Issues recommendations on reimbursement
- Defines medical guidelines
- Informs all actors

**CNAMTS**
- MSA
- RSI
- Propose and manage their budget

**UNCAM**
- Propose and manage their budget
- May adjust reimbursement rates within the limits set by the State
- Negociates with health care professionnals

**HOSPITAL COMMITTEE**
- Takes part in price setting decisions

**HOSPITALS**
- Treat

**CEPS (Economic Committee)**
- Takes part in pharmaceutical policy decisions

**HEALTH CARE PROFESSIONNALS**
- Coordinate
- Reimburse

**PHARMACEUTICALS**
- Treat

**PATIENT**
- Delegate

**Key to abbreviations:**

- **CEPS** Comité Economique des Produits de Santé: Economic Committee for Health Care Products
- **CNAMTS** Caisse Nationale d'Assurance Maladie des Travailleurs Salariés: National Health Insurance Fund for Salaried Employees
- **HAS** Haute Autorité de Santé: National Authority for Health
- **MSA** Mutualité Sociale Agricole: Agricultural Mutual Health Insurance Fund Health (for farmers and farm employees)
- **RSI** Régime Social des Indépendants: National Insurance Fund for Self-employed Workers
- **CPAM** Caisse Primaire d'Assurance Maladie: Local health insurance of CNAMTS
- **URCAM** Union Régionale des Caisses d'Assurance Maladie: Regional Union of Health Insurance Funds (equivalent of UNOCAM at regional level)
- **UNOCAM** Union Nationale des Organismes d'assurance maladie Complémentaires: National Union of Complementary Health Insurance and Mutual Funds
The French health insurance system is based on three main principles:

- equal access to treatment for all citizens, regardless of their place of residence and income;
- quality of treatment;
- solidarity – everyone must contribute to the health insurance scheme according to their income and receive care according to their needs.

Patients must register with a referring doctor (generally a general practitioner - Médecin Généraliste, GP) who acts as a gatekeeper for specialist care. If they fail to do so, they may be reimbursed at a lower level. Outpatient doctors are remunerated on a fee-for-service basis. Hospitals are remunerated through a combination of annual fixed budgets and fee-for-service payments.

**PHARMACEUTICAL SYSTEM**

Key actors of the pharmaceutical system are listed here:

- The French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS), through a Market Authorisation Commission, is responsible for granting market authorisation. The French Health Products Safety Agency (AFSSAPS) is also in charge of classification, vigilance and advertisement control.

- The French National Authority for Health (Haute Autorité de Santé, HAS), through the Transparency Commission (Commission de la Transparence), is in charge of assessing medical service and improvement of medical service provided. The French National Authority for Health (HAS) gives technical advice on including pharmaceuticals on the positive list of reimbursable pharmaceuticals and issues recommendations. As of 2008, the HAS is also in charge of conducting pharmaco-economic evaluations.

- The Economic Committee for Health Care Products (CEPS) is in charge of cost-efficacy assessment and price-volume negotiations. The Economic Committee for Health Care Products (CEPS) sets reference prices (Tarif Forfaitaire de Responsabilité, TFR) and the prices of reimbursable pharmaceuticals, as well as the prices of a list of hospital products (pharmaceuticals outside the fee for service payment scheme).

- The National Union of Health Insurance Funds (UNCAM) sets the reimbursement rates for reimbursable pharmaceuticals.

There are 337 pharmaceutical companies based in France. The French market is the fourth largest market in the world with a market share of 5.4%. The leading pharmaceutical manufacturer is Sanofi-Aventis with a market share of 16%, followed by Pfizer, GlaxoSmithKline,
AstraZeneca and Bristol Myers Squibb. France’s pharmaceutical turnover is the highest in Europe (€ 40,585 Mio. in 2005).

In 2006 there were 11 wholesalers with 190 outlets. The total number of pharmacies included:
- 22,561 private pharmacies
- 1,551 hospital pharmacies dispensing pharmaceuticals to outpatients
- 122 dispensing doctors.

Drugstores are not allowed to dispense pharmaceuticals.

In 2006 the total pharmaceutical expenditure (Dépenses totales de médicaments, TPE) was € 31,942 Mio. A total of 69% of the total pharmaceutical expenditure (TPE) was public expenditure and 31% was private expenditure (2005 data).

**PRICING**

Prices for reimbursable pharmaceuticals are set by the Economic Committee for Health Care Products (CEPS), which is composed of representatives of the Ministry of Social Affairs (Ministère des Affaires Sociales, MAS), Ministry of Health, Ministry of Economy, Finance and Employement (Ministère de l’Economie, des Finances et de l’Emploi, MINEFE), compulsory Health Insurance Funds and complementary Health Insurance Funds.

Pricing policies in France include:
- statutory pricing for reimbursable products. Price are negotiated between the Economic Committee for Health Care Products (CEPS) and pharmaceutical manufacturers, along with a 3-year agreement known as “accord cadre”, the ongoing one being effective until 31 December 2009;
- free pricing for non-reimbursable pharmaceuticals and most pharmaceuticals approved for hospital use and for over-the-counter (OTC) pharmaceuticals (Médicament en vente libre).

Prices are set at ex-factory level. Pharmacy retail prices (PRP) for reimbursable pharmaceuticals (including wholesalers’ and pharmacists’ margins) are regulated as well.

Only pharmaceuticals that provide an improvement in medical service or savings in the cost of treatment are eligible for reimbursement by the Health Insurance Funds (art. R 163-5 of the Social Security Code (Code de la Sécurité Sociale, CSS). The price of highly innovative pharmaceuticals (Level of improvement of clinical benefit (“Amélioration du service médical rendu”, ASMR) levels I to III) must be consistent with the prices of similar pharmaceuticals in other European countries.

ASMR (Level of improvement of clinical benefit) has been rated on scale of levels I to V:
- ASMR I: major improvement (new therapeutic area, reduction of mortality)
- ASMR II: significant improvement in efficacy and/or reduction of side-effects
- ASMR III: modest improvement in efficacy and/or reduction of side-effects
• ASMR IV: minor improvement
• ASMR V: no improvement.

According to the agreement ("accord cadre") between the Economic Committee for Health Care Products (CEPS) and the Association of Pharmaceutical Industry (Les Entreprises du Médicament, LEEM), the price of pharmaceuticals with Level of improvement of clinical benefit (ASMR) ≥ III should not be lower than the cheaper price observed in comparable European countries, i.e. Germany, Spain, Italy and the United Kingdom, over a period of five years starting from their inclusion in the positive list of reimbursable products.

Table 0.1: France - Wholesale mark up scheme for reimbursable pharmaceuticals, 2008

<table>
<thead>
<tr>
<th>Ex-factory price in € (excluding value-added tax (VAT))</th>
<th>Maximum mark up as a % of ex-factory price</th>
<th>Wholesale price in € (excluding VAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.00-22.90 example 22.90</td>
<td>9.93</td>
<td>25.17</td>
</tr>
<tr>
<td>22.91-150.00 example 150.00</td>
<td>6.0</td>
<td>159.90</td>
</tr>
<tr>
<td>150.00-400 example 400</td>
<td>2.0</td>
<td>414.90</td>
</tr>
<tr>
<td>&gt;400 example 1000</td>
<td>0</td>
<td>1014.90</td>
</tr>
</tbody>
</table>

Source: CNAMTS, Decree of 4 August 1987, current version, modified by Decree of 6 March 2008

Table 0.2: France - Pharmacy mark up scheme for reimbursable pharmaceuticals, 2008

<table>
<thead>
<tr>
<th>Ex-factory price in € (excluding value-added tax (VAT))</th>
<th>Maximum mark up in % of ex-factory price + € 0.53 per pack excluding VAT</th>
<th>Public price in € excluding VAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.00-22.90 example 22.90</td>
<td>26.1</td>
<td>31.68</td>
</tr>
<tr>
<td>22.91-150.00 example 150</td>
<td>10.0</td>
<td>179.12</td>
</tr>
<tr>
<td>&gt;150.00 example 400</td>
<td>6.0</td>
<td>449.12</td>
</tr>
</tbody>
</table>

Source: CNAMTS

For reimbursable pharmaceuticals, wholesalers and pharmacists are remunerated through a regressive mark up scheme. Both wholesalers' and pharmacists' margins are regulated. Margins are free for non-reimbursable pharmaceuticals.

The standard value-added tax (Taxe sur la Valeur Ajoutée, VAT) rate in France is 19.6% on most products and services. The value-added tax (VAT) rate is 2.1% on reimbursable pharmaceuticals and 5.5% on non-reimbursable pharmaceuticals.
Pharmaceutical companies must commit themselves to submitting prices similar to those granted in Germany, Spain, Italy and the United Kingdom. In the event of a price change in one or more of the above-mentioned countries, they also commit themselves to adjusting their prices so that they remain consistent with the new prices in those countries. If actual sales are above the sales forecasts planned for the first four years after launching a product (these forecasts must be included in the price application report), the company must reimburse the State for the extra costs borne by Health Insurance Funds.

**REIMBURSEMENT**

- The National Union of Health Insurance Funds (UNCAM) is in charge of setting the reimbursement rate after assessment of medical service and improvement of medical service by the Transparency Commission and evaluation of clinical added value and simultaneously of the pricing procedure by the Economic Committee for Health Care Products (CEPS).

- There is a positive list of reimbursable pharmaceuticals which is determined by the Ministry of Health after receiving technical advice from the Transparency Commission and price decision from the CEPS. Only pharmaceuticals that provide an improvement of medical service or savings in the cost of treatment are eligible for reimbursement.

- The National Union of Health Insurance Funds (UNCAM) has been in charge of defining the reimbursement categories since 13 August 2004 (Art. L322-2 and L182-2 of the Social Security Code (CSS)). There are three reimbursement categories (cf. Table 4.1). The reimbursement rate is based on HAS recommendation Clinical Benefit Assessment (“Service Médical Rendu”, SMR) and seriousness of disease.

*Table 0.3: France - Reimbursement categories and rates*

<table>
<thead>
<tr>
<th>Reimbursement category by clinical benefit (SMR)</th>
<th>Reimbursement rate for serious disease</th>
<th>Reimbursement rate for non-serious disease</th>
<th>Characteristic of category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td>65%</td>
<td>35%</td>
<td>Normal rate determined by Minister of Health, UNCAM can modify it, +or - 5 points</td>
</tr>
<tr>
<td>Moderate</td>
<td>35%</td>
<td>35%</td>
<td>Normal rate determined by Minister of Health, UNCAM can modify it, +or - 5 points</td>
</tr>
<tr>
<td>Weak</td>
<td>35%</td>
<td>35%</td>
<td>Rate determined by Minister of Health, UNCAM can modify it, +or - 5 points</td>
</tr>
<tr>
<td>Insufficient</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
</tbody>
</table>

UNCAM = National Union of Health Insurance Funds

There is a reference price system in France for a list of 207 generic groups, “le répertoire”. The list was first introduced on 27 August 2003. The reference price (TFR) is generally equal to the generic price. The list and reference prices (TFR) are the responsibility of the Econom-
ic Committee for Health Care Products (CEPS). A new generics group is included in the reference price list each time a poor rate of substitution is observed for this group.

There is no flat prescription fee but a fixed out-of-pocket fee of € 0.5 per package with an annual ceiling of € 50 since January, 1st 2008. Co-payments comprise the difference between the retail price (100%) and the rate of reimbursement.

Most pharmaceuticals dispensed in hospitals to inpatients are included in the daily rate, i.e. in the hospital’s fee-for-service payment system. However, for some highly innovative pharmaceuticals from a specific list for hospital use with regulated prices, hospitals can claim reimbursement from the Health Insurance Funds from 70 to 100% depending on the contract of good use with the Health Insurance in addition to the daily rate. For pharmaceuticals dispensed to outpatients, hospitals claim reimbursement directly from the Health Insurance Funds, including a margin, but this is gradually changing to a system with a fee-for-service payment per dispensation.

According to the Law of 14 August 2004, the National Union of Health Insurance Funds (UNCAM) can increase or reduce the rate of reimbursement by 5% against the current rate, if the annual budget for health expenditure (Dépenses de santé, HE) voted by Parliament is not met.

RATIONAL USE OF PHARMACEUTICALS

Some treatment guidelines have been produced by the French National Authority for Health (HAS). There is no national formulary.

Advertisement of pharmaceuticals is strictly regulated:

- Advertisement of prescription-only medicine(s) (Médicament(s) à prescription obligatoire, POM) is allowed in medical journals only. This type of advertisement is controled “a posteriori” by a special commission of AFSSAPS.

- Advertisement of over-the-counter (OTC) pharmaceuticals is allowed in all media intended for the general public (press, television (TV), etc.). Each campaign must be authorised by the commission “a priori”.

- Recent campaigns have been run by Health Insurance Funds to heighten both doctors’ and patients’ awareness of rational use of antibiotics, tranquillizers, sleeping pills and statins that are over-prescribed in France compared to other European countries.

Pharmacoeconomic studies are not required by law for including a product in the positive list. If a pharmaceutical company produces such a study, it is assessed by the Transparency Commission and the Economic Committee for Health Care Products (CEPS) on an individual basis. Since January 1st 2008, the HAS is in charge of conducting pharmaco-economic evaluations for post-marketed products.

Generic substitution is allowed on a voluntary basis. It is promoted through:

- a financial incentive to pharmacists (higher margin);
• an agreement between the UNCAM and the union of pharmacists to increase the rate of substitution;

• the non-exemption of initial payment of the patient to the pharmacist (the system of direct payment by the health insurance fund to the pharmacist known as “tiers-payant” and applied in most situations);

• and through television (TV) advertising campaigns intended for consumers.

Individual consumption data are available.

**CURRENT CHALLENGES AND FUTURE DEVELOPMENTS**

The pharmaceutical expenditure (Dépenses de médicaments, PE) of the compulsory health insurance schemes slightly increased by 2% from 2005 to 2006, partly due to price reductions over the period, generic policy, de-listing and cuts in the reimbursement rate of some pharmaceuticals, price cuts in brand name pharmaceuticals, etc. In 2007 the expenditures of pharmaceuticals have grown up at an annual rate of 4.8%.
# Table of content

Executive summary .......................................................................................................................... III

Table of content ................................................................................................................................ XI

List of tables and figures .................................................................................................................... XIV

List of abbreviations ........................................................................................................................ XVI

PPRI Pharma Profile Update 2008 ...................................................................................................... XVII

1 Background .................................................................................................................................. 1

2 Pharmaceutical system .................................................................................................................... 6
  2.1 Organisation ............................................................................................................................. 6
    2.1.1 Regulatory framework ........................................................................................................ 8
      2.1.1.1 Policy and legislation ............................................................................................. 8
      2.1.1.2 Authorities ............................................................................................................. 8
    2.1.2 Pharmaceutical market ....................................................................................................... 13
      2.1.2.1 Availability of pharmaceuticals ............................................................................. 13
      2.1.2.2 Consumption ......................................................................................................... 14
      2.1.2.3 Market data ............................................................................................................ 15
      2.1.2.4 Patents and data protection ................................................................................. 16
    2.1.3 Market players .................................................................................................................... 17
      2.1.3.1 Industry .................................................................................................................. 18
      2.1.3.2 Wholesalers .......................................................................................................... 21
      2.1.3.3 Pharmaceutical outlets / retailers ........................................................................... 22
        2.1.3.3.1 Pharmacies .................................................................................................... 22
        2.1.3.3.2 Other pharmacy outlets ................................................................................. 26
        2.1.3.3.3 Internet pharmacies ....................................................................................... 26
        2.1.3.3.4 Dispensing doctors .......................................................................................... 26
      2.1.3.4 Hospitals ................................................................................................................... 26
      2.1.3.5 Doctors .................................................................................................................... 27
      2.1.3.6 Patients .................................................................................................................... 27
  2.2 Funding ................................................................................................................................... 28
    2.2.1 Pharmaceutical expenditure .............................................................................................. 28
    2.2.2 Sources of funds .............................................................................................................. 29

3 Pricing ......................................................................................................................................... 32
  3.1 Organisation ............................................................................................................................. 32
  3.2 Pricing policies ........................................................................................................................... 33
    3.2.1 Statutory pricing ............................................................................................................... 34
List of tables and figures

Table 0.1: France - Wholesale mark up scheme for reimbursable pharmaceuticals, 2008 .............. VII
Table 0.2: France - Pharmacy mark up scheme for reimbursable pharmaceuticals, 2008 ............... VII
Table 0.3: France - Reimbursement categories and rates ............................................................. VIII
Table 1.1: France - Key figures on the healthcare system, 2000–2007 ........................................ 4
Table 1.2: France - Diseases with highest morbidity and the leading causes of mortality, 2002 and 2005 .............................................................................................................................. 5
Table 2.1: France - Authorities in the regulatory framework in the pharmaceutical system, 2008...... 13
Table 2.2: France - Number of pharmaceuticals, 2000–2007 .................................................... 14
Table 2.3: France – Annual prescriptions and consumption, 2000–2007 ..................................... 14
Table 2.4: France - Market data, 2000–2006 ................................................................................ 15
Table 2.5: France - Top 10 best-selling pharmaceuticals, by active ingredient, 2006 ..................... 16
Table 2.6: France - Patent registration procedure ...................................................................... 17
Table 2.7: France – Key data on the pharmaceutical industry, 2000–2006 ..................................... 21
Table 2.8: France - Key data on pharmaceutical wholesale, 2000–2006 ..................................... 22
Table 2.9: France - Retailers of pharmaceuticals, 2000–2007 ..................................................... 24
Table 2.10: France - Total pharmaceutical expenditure, 2000–2007 ............................................. 29
Table 3.1: France - Ways of pricing pharmaceuticals, 2008 .......................................................... 33
Table 3.2: France - Pricing procedures, 2008 ............................................................................. 35
Table 3.3: France - Regulation of wholesale and pharmacy mark ups, 2008 ............................... 39
Table 3.4: France - Structure covered by social insurance, i.e. for reimbursable pharmaceuticals... 39
Table 3.5: France - Wholesale mark up scheme for reimbursable pharmaceuticals, 2008 ............ 40
Table 3.6: France - Pharmacy mark up scheme for reimbursable pharmaceuticals, 2008 ............. 40
Table 3.7: France - Price reviews and price cuts, 2002–2008 ....................................................... 43
Table 4.1: France - Number of persons covered by the different health insurance schemes, 2000–2005 ............................................................................................................................. 49
Table 4.2: France - Reimbursement of pharmaceuticals ................................................................. 49
Table 4.3: France - Exceptions for reimbursement of pharmaceuticals ........................................ 50
Table 4.4: France - Average reimbursement rates 1995, 2000–2006 .............................................. 51
Table 4.5: France - An overview of the growth of the amount paid by health insurance funds, 2000–2005 ........................................................................................................................................... 55
Table 5.1: France - Development of the generics market in the outpatient sector, 2000–2007 ......... 61
Table 6.1: France – Changes in the pharmaceutical system, 2005–2008 ........................................... 65
Figure 1: France - Main actors in the health care system ................................................................. IV
Figure 2.1: France - Flowchart of the pharmaceutical system for reimbursable pharmaceuticals, 2008 ......................................................................................................................................... 7
Figure 2.2: France - Health insurance organisation, 2006 ......................................................................................................................................... 10
Figure 2.3: France - Pharmaceutical distribution channels in % of turnover at ex-factory price (excluding overseas territories), 2006 ......................................................................................................................................... 18
Figure 2.4: France - Number of community pharmacies and number of inhabitants per pharmacy, 2000–2006 ......................................................................................................................................... 25
Figure 2.5: France - Share of private and public outpatient pharmaceutical expenditure, 2006 ........ 31
Figure 4.1: France - Development of pharmaceuticals in Reimbursement Code ............................. 50
# List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
<th>Full Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>AESGP</td>
<td>Association of the European Self-Medication Industry</td>
<td>Association Européenne de l’industrie de l’auto-médication</td>
</tr>
<tr>
<td>AFIPA</td>
<td>French Association of Self-medication Industry</td>
<td>Association Française de l’Industrie Pharmaceutique pour une Automédication responsable</td>
</tr>
<tr>
<td>AFSSET</td>
<td>French Agency for Environmental and Occupational Health Safety</td>
<td>Agence Française de Sécurité Sanitaire de l’Environnement et du Travail</td>
</tr>
<tr>
<td>AFSSA</td>
<td>French Food Safety Agency</td>
<td>Agence Française de Sécurité Sanitaire des Aliments</td>
</tr>
<tr>
<td>AFSSAPS</td>
<td>French Health Products Safety Agency</td>
<td>Agence Française de Sécurité Sanitaire des Produits de Santé</td>
</tr>
<tr>
<td>ALD</td>
<td>Long-Term Illness</td>
<td>Affection de longue durée</td>
</tr>
<tr>
<td>AME</td>
<td>State Medical Aid</td>
<td>Aide Médicale d’Etat</td>
</tr>
<tr>
<td>APR</td>
<td>Federation of Rural Pharmacies</td>
<td>Association des Pharmacies Rurales</td>
</tr>
<tr>
<td>ASMR</td>
<td>Level of improvement of clinical benefit</td>
<td>Amélioration du service médical rendu</td>
</tr>
<tr>
<td>ATC</td>
<td>Anatomic Therapeutic Chemical classification</td>
<td>Classification Anatomique, Thérapeutique, Chimique</td>
</tr>
<tr>
<td>ATU</td>
<td>Temporary Utilisation Authorisation</td>
<td>Autorisation temporaire d’utilisation</td>
</tr>
<tr>
<td>CANAM</td>
<td>Health Insurance Fund for Independent Professions</td>
<td>Caisse d’Assurance Maladie des Professions Indépendantes</td>
</tr>
<tr>
<td>CNAF</td>
<td>National Fund For Family Allowances</td>
<td>Caisse Nationale d’Allocations Familiales</td>
</tr>
<tr>
<td>CCP</td>
<td>Complementary Protect Certificate</td>
<td>Certificat Complémentaire de Protection</td>
</tr>
<tr>
<td>CEPS</td>
<td>Economic Committee for Health Care Products</td>
<td>Comité Economique des Produits de Santé</td>
</tr>
<tr>
<td>CGPME</td>
<td>General Confederation of Small and Medium-sized Enterprises</td>
<td>Confédération Générale des petites et moyennes entreprises</td>
</tr>
<tr>
<td>CMU</td>
<td>Universal Health Insurance Coverage</td>
<td>Couverture Maladie Universelle</td>
</tr>
<tr>
<td>CMUC</td>
<td>Complementary Universal Insurance Health Coverage</td>
<td>Couverture Maladie Universelle Complémentaire</td>
</tr>
<tr>
<td>XVI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
<td>French Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>CNAMTS</td>
<td>National Health Insurance Fund for Salaried Employees</td>
<td>Caisse Nationale d’Assurance Maladie des Travailleurs Saliéris</td>
</tr>
<tr>
<td>CNAVTS</td>
<td>National Elderly Insurance Fund for Salaried Employees</td>
<td>Caisse Nationale d’Assurance Vieillesse des Travailleurs Saliéris</td>
</tr>
<tr>
<td>CNOP</td>
<td>Pharmacist Professional Board</td>
<td>Conseil National de l’Ordre des Pharmaciens</td>
</tr>
<tr>
<td>CPAM</td>
<td>Local level of CNAMTS</td>
<td>Caisse Primaire d’Assurance Maladie</td>
</tr>
<tr>
<td>COG</td>
<td>Management and Objectives Contract</td>
<td>Contrat d’Objectif et de Gestion</td>
</tr>
<tr>
<td>CPG</td>
<td>Pluriannual Management Contracts</td>
<td>Contrat pluri-annuel de gestion</td>
</tr>
<tr>
<td>CPI</td>
<td>Intellectual Property Code</td>
<td>Code de la Propriété Intellectuelle</td>
</tr>
<tr>
<td>CRDS</td>
<td>Tax for reimbursement of social debt</td>
<td>Contribution pour le remboursement de la dette sociale</td>
</tr>
<tr>
<td>CSG</td>
<td>General Social Contribution</td>
<td>Contribution Sociale Généralisée</td>
</tr>
<tr>
<td>CSMF</td>
<td>Confederation of French Medical Unions</td>
<td>Confédération des Syndicats Médicaux Français</td>
</tr>
<tr>
<td>CSP</td>
<td>Public Health Code</td>
<td>Code de la Santé Publique</td>
</tr>
<tr>
<td>CSRP</td>
<td>Wholesalers Union</td>
<td>Chambre Syndicale des Répartiteurs Pharmaceutiques</td>
</tr>
<tr>
<td>CSS</td>
<td>Social Security Code</td>
<td>Code de la Sécurité Sociale</td>
</tr>
<tr>
<td>DAM</td>
<td>Health Insurance Representative</td>
<td>Délégué de l’Assurance Maladie</td>
</tr>
<tr>
<td>DG</td>
<td>Health and Consumer protection Directorate General - EC</td>
<td>Direction Générale Santé et Protection du Consommateur - EC</td>
</tr>
<tr>
<td>SANCO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMP</td>
<td>Electronic health record</td>
<td>Dossier Médical Personnel</td>
</tr>
<tr>
<td>DP</td>
<td>Electronic pharmaceutical record</td>
<td>Dossier Pharmaceutique</td>
</tr>
<tr>
<td>EC</td>
<td>European Commission</td>
<td>Commission Européenne</td>
</tr>
<tr>
<td>EMEA</td>
<td>European Agency for the Evaluation of Medicinal Products</td>
<td>Agence Européenne du médicament</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
<td>Union Européenne</td>
</tr>
<tr>
<td>FIT</td>
<td>Prescription Guide</td>
<td>Fiche d’Information Thérapeutique</td>
</tr>
<tr>
<td>FMF</td>
<td>Federation of Doctors in France</td>
<td>Fédération des Médecins de France</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Name</td>
<td>Full Name in French</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>FSPF</td>
<td>Federation of Pharmacists in France</td>
<td>Fédération des Syndicats Pharmaceutiques de France</td>
</tr>
<tr>
<td>GEMME</td>
<td>Generic Producers Association</td>
<td>Association des Fabricants de Génériques</td>
</tr>
<tr>
<td>GDP</td>
<td>Gross Domestic Product</td>
<td>Produit intérieur brut</td>
</tr>
<tr>
<td>GGE</td>
<td>General Government Expenditure</td>
<td>Dépenses de l’Etat</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
<td>Médecin Généraliste</td>
</tr>
<tr>
<td>HAS</td>
<td>French National Authority for Health</td>
<td>Haute Autorité de Santé</td>
</tr>
<tr>
<td>HCAAM</td>
<td>High Committee for the Future of Social Security</td>
<td>Haut Conseil pour l’Avenir de l’Assurance Maladie</td>
</tr>
<tr>
<td>HE</td>
<td>Health Expenditure</td>
<td>Dépenses de santé</td>
</tr>
<tr>
<td>HiT</td>
<td>Health Care Systems in Transition</td>
<td>Systèmes de santé en transition</td>
</tr>
<tr>
<td>HOM</td>
<td>Hospital-Only Medicine</td>
<td>Médicament de la réserve hospitalière</td>
</tr>
<tr>
<td>INN</td>
<td>International Nonproprietary Name</td>
<td>Dénomination Commune Internationale</td>
</tr>
<tr>
<td>INCA</td>
<td>French National Cancer Institute</td>
<td>Institut National du Cancer</td>
</tr>
<tr>
<td>INPI</td>
<td>National Institute for Industrial Property</td>
<td>Institut National de la Propriété Industrielle</td>
</tr>
<tr>
<td>INVS</td>
<td>National Institute for Monitoring Public Health</td>
<td>Institut National de la Veille Sanitaire</td>
</tr>
<tr>
<td>LAP</td>
<td>Computer-assisted prescription software</td>
<td>Logiciel d’Aide à la Prescription</td>
</tr>
<tr>
<td>LEEM</td>
<td>Association of Pharmaceutical Industry</td>
<td>Les Entreprises du Médicament</td>
</tr>
<tr>
<td>LFSS</td>
<td>Finance Law of the Social Security System</td>
<td>Loi de financement de la sécurité sociale</td>
</tr>
<tr>
<td>MAS</td>
<td>Ministry of Social Affairs</td>
<td>Ministère des Affaires Sociales</td>
</tr>
<tr>
<td>MEDEF</td>
<td>French Business Confederation</td>
<td>Mouvement des Entreprises Françaises</td>
</tr>
<tr>
<td>MG France</td>
<td>French Federation of General Practitioners</td>
<td>Fédération française des médecins généralistes</td>
</tr>
<tr>
<td>Mio.</td>
<td>Million</td>
<td>Million</td>
</tr>
<tr>
<td>MINEFE</td>
<td>Ministry of Economy, Finance and Employment</td>
<td>Ministère de l’Economie, des Finances et de l’Emploi</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
<td>Translation</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>MSA</td>
<td>Agricultural Mutual Insurance Fund (for farmers and farm employees)</td>
<td>Mutualité Sociale Agricole</td>
</tr>
<tr>
<td>NCU</td>
<td>National Currency Unit</td>
<td>Monnaie nationale</td>
</tr>
<tr>
<td>ÖBIG</td>
<td>Austrian Health Institute</td>
<td>Institut de santé Autrichien</td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Co-operation and Development</td>
<td>Organisation de coopération et de développement économiques</td>
</tr>
<tr>
<td>ONDAM</td>
<td>National Target for Health Insurance Expenditure</td>
<td>Objectif National des Dépenses d'Assurance Maladie</td>
</tr>
<tr>
<td>OPP</td>
<td>Out-of-Pocket Payment</td>
<td>Reste à charge ou ticket modérateur</td>
</tr>
<tr>
<td>OTC</td>
<td>Over-The-Counter pharmaceuticals</td>
<td>Médicament en vente libre</td>
</tr>
<tr>
<td>PE</td>
<td>Pharmaceutical Expenditure</td>
<td>Dépenses de médicaments</td>
</tr>
<tr>
<td>POM</td>
<td>Prescription-Only Medicines</td>
<td>Médicament à prescription obligatoire</td>
</tr>
<tr>
<td>PPI</td>
<td>Proton Pump Inhibitor(s)</td>
<td>Inhibiteur(s) de la Pompe à Protons (IPP)</td>
</tr>
<tr>
<td>PPP</td>
<td>Pharmacy Purchasing Price</td>
<td>Prix d’achat des médicaments par les pharmaciens</td>
</tr>
<tr>
<td>PPRI</td>
<td>Pharmaceutical Pricing and Reimbursement Information project</td>
<td>Nom d’un projet sur d’information des prix et du remboursement de médicaments</td>
</tr>
<tr>
<td>PRP</td>
<td>Pharmacy Retail Price</td>
<td>Prix à la consommation ou prix public</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research and Development</td>
<td>Recherche et Développement</td>
</tr>
<tr>
<td>ROR</td>
<td>Rubeola-Mumps-Roseola</td>
<td>Rougeole-Oreillons-Rubéole</td>
</tr>
<tr>
<td>RSI</td>
<td>National Insurance Fund for Self-employed Workers</td>
<td>Régime Social des Indépendants</td>
</tr>
<tr>
<td>SD</td>
<td>Self-Dispensing Doctors</td>
<td>Médecins pro-pharmaciens</td>
</tr>
<tr>
<td>SEL</td>
<td>Incorporated Company(ies)</td>
<td>Société(s) d’Exercice Libéral</td>
</tr>
<tr>
<td>SHI</td>
<td>Social Health Insurance</td>
<td>Assurance sociale</td>
</tr>
<tr>
<td>SML</td>
<td>Union of Self-Employed Doctors</td>
<td>Syndicat des Médecins Libéraux</td>
</tr>
<tr>
<td>SMR</td>
<td>Clinical benefit</td>
<td>Service médical rendu</td>
</tr>
<tr>
<td>SPC</td>
<td>Summary of Product Characteristics</td>
<td>Résumé des caractéristiques du produit</td>
</tr>
<tr>
<td>TFR</td>
<td>Reference price</td>
<td>Tarif Forfaitaire de Responsabilité</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>French Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>THE</td>
<td>Total Health Expenditure</td>
<td>Dépenses totales de santé</td>
</tr>
<tr>
<td>TPE</td>
<td>Total Pharmaceutical Expenditure</td>
<td>Dépenses totales de médicaments</td>
</tr>
<tr>
<td>TV</td>
<td>Television</td>
<td>Télévision</td>
</tr>
<tr>
<td>UNCAM</td>
<td>National Union of Social Health Insurance Funds</td>
<td>Union Nationale des Caisses d'Assurance Maladie</td>
</tr>
<tr>
<td>UNOCAM</td>
<td>National Union of complementary insurance and mutual funds</td>
<td>Union Nationale des Organismes Complémentaires d'Assurance Maladie</td>
</tr>
</tbody>
</table>
PPRI Pharma Profile Update 2008

Rationale

In the beginning, the Pharmaceutical Pricing and Reimbursement Information (PPRI) project was a 31 month-project (2005-2007) commissioned by the Health and Consumer Protection Directorate-General (DG SANCO) of the European Commission and co-funded by the Austrian Federal Ministry of Health, Family and Youth (Bundesministerium für Gesundheit, Familie und Jugend, BMGFJ). The project was coordinated by the main partner Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG (GÖG/ÖBIG) and the associated partner World Health Organisation (WHO) Regional Office for Europe. The PPRI project has established a network of more than 50 participating institutions (competent authorities and other relevant organisations) in the field of pharmaceuticals (for the list of PPRI members see the PPRI website http://ppri.oebig.at → Network)

Within the course of the PPRI project, country reports on pharmaceutical pricing and reimbursement systems, the “so-called PPRI Pharma Profiles”, were produced (see http://ppri.oebig.at → Publications → Country Information. These PPRI Pharma Profiles refer, in general, to the year 2006/2007. The works was mainly under the responsibility of the WHO Regional Office for Europe assisted by the team of the Gesundheit Österreich GmbH, Geschäftsbereich ÖBIG / Austrian Health Institute (GÖG/ÖBIG).

Despite of the official end of the research project in 2007, the PPRI network participants have agreed to continue the network and up-date the PPRI Pharma Profiles.

Outline

The PPRI Pharma Profile consists of six chapters, referring to the situation in 2008:

- Chapter 1 (Background) gives a brief overview of the demographic, economic and political situation and a brief introduction to the health care system.
- Chapter 2 (Pharmaceutical system) provides a description of the pharmaceutical system; the regulatory framework, the pharmaceutical market, the market players and the funding of pharmaceuticals and the methods of evaluating the system.
- Chapter 3 (Pricing) covers a description of the organisation of the pricing system, the pricing policies, the pricing procedures, exceptions to these procedures, as well as a section on margins and taxes and pricing related cost-containing measures.
- Chapter 4 (Reimbursement) covers a description of the organisation of the reimbursement system, the reimbursement scheme including the eligibility criteria, the reimbursement categories and rates and the reimbursement lists. Also described in this chapter is the reference price system, the private pharmaceutical expenditure, the reimbursement in the hospital sector and the reimbursement related cost-containing measures.
- Chapter 5 (Rational Use of Pharmaceuticals) is a description of the methods used to improve rational use of pharmaceuticals including the impact of pharmaceutical budget, prescription guidelines, patient information, pharmaco-economics, generics and consumption.
• Chapter 6 (Current challenges and future developments) is a concluding chapter on the current challenges and future plans for developments in the pharmaceutical sector.

Further deliverables

Besides the PPRI Pharma Profiles and the PPRI network, the PPRI project produced further deliverables, among those:

• The **PPRI Glossary**, which is a unique glossary of pharmaceutical terms to establish a common "pharma" terminology within the EU. See http://ppri.oebig.at → Glossary

• The **PPRI Conference**, held in Vienna in June 2007. See http://ppri.oebig.at → Conferences → PPRI Conference

• The **Set of Core PPRI Indicators** to compare information of different pharmaceutical system. See http://ppri.oebig.at → Publications → Indicators

• A comparative analysis, based on the developed indicators, filled with real data from 27 PPRI countries. The PPRI comparative analysis is included in the **PPRI Report** and summed up in the concise report "**PPRI at a Glance**". See http://ppri.oebig.at → Publications → PPRI Report and http://ppri.oebig.at → Publications → Concise Information

Contact

The PPRI Secretariat is located at Gesundheit Österreich GmbH, Geschäftsbereich Österreichisches Bundesinstitut für Gesundheitswesen / Austrian Health Institute (GÖG/ÖBIG) which featured as the main partner of the PPRI research project.

Gesundheit Österreich GmbH, Geschäftsbereich Österreichisches Bundesinstitut für Gesundheitswesen / Austrian Health Institute (GÖG/ÖBIG)
Stubenring 6, 1010 Vienna, Austria
E-Mail: ppri@goeg.at
Fax.: +43 1 5138472
URL: http://ppri.oebig.at

Dr. Sabine Vogler, PPRI Project Manager, E-Mail: vogler@goeg.at, Tel.: + 43-1-51561/147
Mag. Claudia Habl, Deputy Project Manager, E-mail: habl@goeg.at, Tel.:+ 43-1-51561/161
Mag. Christine Leopold, MSc., Communication Officer & Editor-in-Chief, E-mail: leopold@goeg.at, Tel. +43-1-51561/149
1 Background

Chapter 1 aims to provide an overview on the country, in particular on the health care system. As the focus of the PPRI Pharma Profiles is on pharmaceutical pricing and reimbursement, the authors of this Profile did not write a full chapter, as they did for the following ones, but opted for the presentation of some key figures on the health care system, presented in two tables and accompanied by a brief description of the health care system.

The French social security system was first implemented in 1945. It aimed at providing compulsory protection against the risks of old age, illness, maternity, occupational accidents and family responsibility for trade and industry employees, funded by contributions collected from wages. In 1961, a compulsory health insurance scheme for farmers was implemented. In 1967, social security was split up into three separate branches, as shown here.

- Health branch: French National Health Insurance Fund for Salaried Employees (CNAMTS).
- Family branch: French National Fund for Family Allowances (Caisse Nationale d'Allocations Familiales, CNAF).

In 1996, a social security reform plan implemented a "universal health insurance scheme" enabling the automatic right to social security for all people aged 18 and over who regularly live in France. Control of health expenditure (Dépenses de santé, HE) was also implemented. A new tax for reimbursement of social debt (Contribution pour le remboursement de la dette sociale, CRDS) was levied on all types of income (not only wages) to ensure additional funding.

In 2000, a Universal Health Insurance Coverage (Couverture Maladie Universelle, CMU) was created for low-income people who cannot afford to become a member of a voluntary health insurance (Assurance complémentaire, VHI) scheme. The Carte Vitale (individual health ID smart card for all people aged 16 and over) was introduced.

In 2004, the particularly worrying financial situation of the health insurance system led the Government to take action regarding the organisation of the available health care and the control of health expenditure (HE), as well as changes in the National Insurance Fund for Salaried Employees’ (Caisse Nationale d'Assurance Maladie des Travailleurs Salarisés, CNAMTS) managerial bodies. The overall objective of the reform was "better care through better expenditure".

The French health insurance system is based on three main principles:

- equal access to treatment for all citizens, regardless of their place of residence and income;
- quality of treatment;
- solidarity – everyone must contribute to the health insurance scheme according to their income and receive care according to their needs.

The health insurance system is divided into three main schemes, as listed here.
The general scheme, which covers employees in the industry, business and services sectors, covers 85% of the French population. It is managed by the National Insurance Fund for Salaried Employees (CNAMTS).

The agricultural scheme, which covers farmers and farm employees (about 7% of the population covered), is managed by the Agricultural Mutual Insurance Fund (Mutualité Sociale Agricole, MSA).

The scheme for non-salaried and non-farming, self-employed workers (about 5% of the population covered), which covers craftspeople, retailers and independent professions, is managed by various organisations belonging to the National Insurance Fund for Self-employed Workers (Régime Social des Indépendants, RSI).

The system also includes a number of other special schemes (sailors, miners, railway employees, Paris public transport employees, employees from the Electricity and Gas Board, etc.)

The new organisation mechanism for steering the health insurance system involves (as of 13 August 2004) the steps set out here.

- The creation of the National Union of Health Insurance Funds (Union Nationale des Caisses d’Assurance Maladie, UNCAM), which is a new body bringing together the three major health insurance schemes in order to:
  - run the conventional policy (i.e. the agreements between the Health Insurance Funds and the health care providers);
  - define the scope of services eligible for reimbursement;
  - set up the health care reimbursement tariffs.

- Extended powers for the National Insurance Fund for Salaried Employees (CNAMTS) Managing Director, who:
  - is also the Managing Director of the National Union of Health Insurance Funds (UNCAM) and carries out National Union of Health Insurance Funds (UNCAM) missions within the framework of adopted guidelines and within the given term of office;
  - appoints managers and accountants for the bodies;
  - takes the necessary measures for the successful organisation and steering of the network;
  - negotiates the Management and Objectives Agreement (Convention d’Objectifs et de Gestion, COG) with the State and the resulting Pluriannual Management Contracts (Contrats Pluriannuels de Gestion, CPG) with the bodies;
  - may suspend or cancel the decision of a Council or of a local or regional body which would not be aware of the commitments concluded in the Management and Objectives Agreement (COG) or a Pluriannual Management Contract (CPG).

- The reorganised National Insurance Fund for Salaried Employees (CNAMTS) Council:
  - is marked by the return of employers’ representatives and open to representatives of mutual insurance companies and other institutions in the health insurance sector
  - has been set up to define the risk management policy guidelines and to clarify the modalities for implementing the health care policy and organisation of the health care system.
• The creation of the French National Authority for Health (Haute Autorité de Santé, HAS):
  - as the body created to define the scope of reimbursable treatments;
  - which conducts periodic evaluations of medical services, draws up recommendations
    for good medical practices and conducts from 2008 on pharmaco-economic evaluations,

• Better representation of the Health Insurance System within the Economic Committee for
  Health Care Products (Comité Economique des Produits de Santé, CEPS), which:
  - sets up the price of pharmaceuticals;
  - establishes the “Tarif forfaitaire de responsabilité” (fixed amount on the basis of which
    Health Insurance Funds reimburse some groups of generic pharmaceuticals).

For further information, please refer to the document entitled “The General Health Insurance
Scheme”, published by the National Insurance Fund for Salaried Employees (CNAMTS) in
2006.
## Table 1.1: France - Key figures on the healthcare system, 2000–2007

<table>
<thead>
<tr>
<th>Variable</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (millions)</td>
<td>59,049</td>
<td>59,454</td>
<td>59,863</td>
<td>60,264</td>
<td>60,643</td>
<td>60,996</td>
<td>61,353</td>
<td>61,707*</td>
</tr>
<tr>
<td>Life expectancy at birth, total</td>
<td>79.0</td>
<td>79.2</td>
<td>79.4</td>
<td>79.4</td>
<td>80.3</td>
<td>80.3</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Females</td>
<td>82.8</td>
<td>82.9</td>
<td>83.0</td>
<td>82.9</td>
<td>83.9</td>
<td>83.8</td>
<td>84.2</td>
<td>84.5*</td>
</tr>
<tr>
<td>Males</td>
<td>75.3</td>
<td>75.5</td>
<td>75.8</td>
<td>75.9</td>
<td>76.8</td>
<td>76.8</td>
<td>77.2</td>
<td>77.6</td>
</tr>
<tr>
<td>GDP in Billion €</td>
<td>1 441,4</td>
<td>1 497,2</td>
<td>1 548,6</td>
<td>1 594,8</td>
<td>1 660,2</td>
<td>1 717,9</td>
<td>1 792,0</td>
<td>n.a.</td>
</tr>
<tr>
<td>GGE in million €</td>
<td>320,3</td>
<td>330,3</td>
<td>349,9</td>
<td>355,6</td>
<td>376,6</td>
<td>387,8</td>
<td>380,4</td>
<td>n.a.</td>
</tr>
<tr>
<td>Total Health Expenditure in Mio. €</td>
<td>138,294</td>
<td>145,511</td>
<td>155,034</td>
<td>173,677</td>
<td>182,866</td>
<td>190,951</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Private Health Expenditure in Mio. €</td>
<td>29,965</td>
<td>31,518</td>
<td>33,175</td>
<td>35,849</td>
<td>37,654</td>
<td>38,504</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Total number of hospitals</td>
<td>n.a.</td>
<td>n.a.</td>
<td>3,022</td>
<td>2,987</td>
<td>2,933</td>
<td>2,890</td>
<td>2,856</td>
<td>n.a.</td>
</tr>
<tr>
<td>Number of acute care beds</td>
<td>240,817</td>
<td>235,833</td>
<td>234,756</td>
<td>230,727</td>
<td>228,134</td>
<td>224,030</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Total number of doctors</td>
<td>113,994</td>
<td>114,242</td>
<td>114,227</td>
<td>113,866</td>
<td>114,16</td>
<td>114,626</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Number of visits to General Practitioners per patient per year</td>
<td>5,7</td>
<td>5,8</td>
<td>6,0</td>
<td>5,9</td>
<td>5,9</td>
<td>5,8</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
</tbody>
</table>
Outpatient doctors are remunerated on a fee-for-service basis. Hospitals are remunerated partly through ex-ante annual fixed budgets (approximately 75%) and partly on a fee-for-service basis (approximately 25%), which is being gradually implemented and is expected to account for 100% of hospital remuneration in 2008.

Public pharmaceutical expenditure (Dépenses de medicaments, PE) (social security and state or local funds) accounted for 69% of outpatient pharmaceutical expenditure (PE) in 2006. The remaining 31% from private expenditure included 19% of expenses for private health insurance and 12% out-of-pocket payments (Reste à charge ou ticket modérateur, OPP) (including cost-sharing and self-medication) by households.

Private health insurance in France corresponds to complementary health insurance which patients subscribe to on a (usually) voluntary basis. A total of 93% of the population is covered by complementary health insurance, including 4% covered by the free Complementary Universal Health Insurance Coverage (CMUC), provided for people with low incomes (cf.2.2).

Table 1.2: France - Diseases with highest morbidity and the leading causes of mortality, 2002 and 2005

<table>
<thead>
<tr>
<th>No.</th>
<th>Top 5 diseases with highest prevalence (1 = most common)</th>
<th>ICD-10 code</th>
<th>No.</th>
<th>Top 5 leading causes of mortality (1 = most common)</th>
<th>ICD-10 code</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Diseases of the digestive system</td>
<td>K00-K93</td>
<td>1</td>
<td>Neoplasms</td>
<td>C00-D48</td>
</tr>
<tr>
<td>2</td>
<td>Diseases of the eye and adnexa</td>
<td>H00-H59</td>
<td>2</td>
<td>Diseases of the circulatory system</td>
<td>I00-I99</td>
</tr>
<tr>
<td>3</td>
<td>Endocrine, nutritional and metabolic diseases</td>
<td>E00-E90</td>
<td>3</td>
<td>Malignant neoplasms</td>
<td>C00-C97</td>
</tr>
<tr>
<td>4</td>
<td>Diseases of the circulatory system</td>
<td>I00-I99</td>
<td>4</td>
<td>Other heart diseases</td>
<td>I30-I33,139-I52</td>
</tr>
<tr>
<td>5</td>
<td>Diseases of the musculoskeletal system and connective tissue</td>
<td>M00-M99</td>
<td>5</td>
<td>Ischaemic heart diseases</td>
<td>I20-I25</td>
</tr>
</tbody>
</table>

Source: DREES Données sur la situation sanitaire et sociale en France, 2005 from ESPS (IRDES)
Self reported morbidity in 2002

Source: EUROSTAT

Year: 2002

Year: 2005
2 Pharmaceutical system

2.1 Organisation

In the following section the authors describe the regulatory framework of the French pharmaceutical system (legal basis, main authorities and their tasks), as well as the French pharmaceutical market (key data and players).

Figure 2.1 depicts only the flowchart for reimbursable pharmaceuticals, from market authorisation to the inscription of reimbursable pharmaceuticals into the positive list. At this stage a pharmaceutical bought in a pharmacy on a prescription by a doctor can be reimbursed by the health insurance funds.

The figures show the positions of the different institutions and their roles in the product life cycle. It is worth noting that after market authorisation a manufacturer can choose to be present only in the hospital sector or only in the non-reimbursable sector.
Figure 2.1: France - Flowchart of the pharmaceutical system for reimbursable pharmaceuticals, 2008

FLOWCHART OF THE PHARMACEUTICAL SYSTEM

Initial Market Authorisation application
(European or national procedure)

EMEA or AFSSAPS

No representative of health insurance funds

Market Authorisation Commission with prescription status
Assessment of benefit/risk ratio and pharmaceutical quality
Commission’s decision

Administrative decision on granting market authorisation

HAS

Transparency Commission
Evaluation of clinical added value and benefit

3 representatives of national health insurance funds with consultative voice

State

CEPS
Based on clinical value, price and volume negotiations

National sickness funds
Reimbursement rate decision

3 representatives of national health insurance funds, 1 for complementary health insurance with voting rights

AFSSAPS

Advertising control and distribution of Rational Drug Use Guidelines Commission

Pharmacovigilance Commission

HAS

Transparency Commission (review every 5 years) and recommendations

Post Marketing Authorisation phase

CEPS – Review of volume conditions and decision on discounts and price changes

AFSSAPS or EMEA

Market authorisation (review every 5 years)

10/04/2006

AFSSAPS: French Health Products Safety Agency
CEPS: Economic Committee for Health Care Products
EMEA: European Medicines Agency
HAS: French National Authority for Health
UNCAM: National Union of Health Insurance Funds

Source: CNAMTS
2.1.1 Regulatory framework

The main players in the French pharmaceutical system are the state bodies at national level (Ministry of Health and Social Security, Minister of Economy, Finance, and Employment (Ministère de l’Économie des Finances et de l’Emploi, MINEFE), which drive policy in this sector, with assistance from the Medicines Agency and the Economic Committee for Health Care Products (CEPS), along with a partial role for health insurance funds. The Parliament votes every year on the Finance Law of the Social Security System (Loi de financement de la sécurité sociale, LFSS); before this vote each year the Court of Accounts produces a report on the application of the Finance Law, policy and legislation. In this Law the National Target for Health Insurance Expenditure (Objectif National des Dépenses d’Assurance Maladie, ONDAM) is voted for.

During the course of the year an independent committee called “Comité d’alerte” analyses the evolution of the expenditure: if the trend shows that the defined target risks to be overlapped it must declare this and the health insurance funds have one month to propose measures to the Government. In 2007, for the first time new measures to control the expenditures have been taken under the committee supervision “Comité d’alerte” (prices cut).

2.1.1.1 Policy and legislation

In the pharmaceutical sector many laws and decrees are in operation, driven by European legislation. They are summarised into two laws (called “Codes”): the Public Health Code (Code de la Santé Publique, CSP\(^8\)) and the Social Security Code (Code de la Sécurité Sociale, CSS\(^9\)).

The regressive statutory mark up schemes for wholesalers and pharmacists are detailed in a decree published in the country's official bulletin\(^{10}\).

2.1.1.2 Authorities

The French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) was created by law on 1 July 1998. It has been effective since 9 March 1999 under the authority of the Ministry of Health. Approximately 900 people are employed and nearly 2,000 experts participate in commissions or working groups. The normal way to obtain market authorisation is under the European Commission (Commission Européenne, EC) Directive 2004/27. The usual time frame for this process is 210 days. A simplified procedure exists for generics by proving the bioequivalence of the pharmaceutical with the original product. There do not seem to be industry problems with delays in obtaining market authorisation; the period of 210 days seems to be enough.

---

\(^{8}\) http://www.legifrance.gouv.fr/affichCode.do?cidTexte=LEGITEXT000006072665&dateTexte=20080606

\(^{9}\) http://www.legifrance.gouv.fr/affichCode.do?cidTexte=LEGITEXT000006073189&dateTexte=20080606

\(^{10}\) http://www.legifrance.gouv.fr/affichTexte.do?dateTexte=&cidTexte=JORFTEXT000018213915&fastPos=1&fastReqI d=935011621&oldAction=rechExpTexteJorf
Before market authorisation is granted, it is possible to put pharmaceuticals on the market with a fast track procedure called a temporary use authorisation (Autorisation temporaire d’utilisation, ATU). Two kinds exist: one for a number of patients of the same type called “ATU de cohorte”. For this procedure it is necessary to conduct the normal studies and obtain a market authorisation. The other type is an agreement, called “ATU nominative”, established on an individual patient basis.

If necessary, a patient can obtain a specific authorisation to import the product if it is not available in France. The Director of the French Health Products Safety Agency (AFSSAPS) implements the sanitary policy on pharmaceuticals and vigilance over pharmaceuticals. Over 70% of the budget of the French Health Products Safety Agency (AFSSAPS) comes from taxes and fees paid by the industry. Health insurance funds are represented in the Board of Directors by one member, but are not represented in the Market Authorisation Commission.

From 1945 to 1986 the prices of all products were under administrative control. Since then, prices have been deregulated, but in the case of a few economic activities, e.g. where there is a monopoly, prices are controlled. In the pharmaceutical sector only reimbursable pharmaceuticals are controlled, whereas in other non-reimbursable sectors there is free pricing, e.g. in hospitals and for over-the-counter (OTC) products (Médicament en vente libre).

Pricing activities are carried out by the Economic Committee for Health Care Products (CEPS) for reimbursable products for outpatients, since 2005 for a list of costly pharmaceuticals outside the fee-for-service payment system of hospitals and for products sold by hospitals to outpatients. Different institutions are represented: the Ministry of Social Affairs (Ministère des Affaires Sociales, MAS), Ministry of Health, Ministry of Economy, Finance and Employment (MINEFE), health insurance funds, complementary insurance and private insurance, the Directorate of Hospitals in the Ministry of Social Affairs (MAS), and the Ministry of Research.

The Economic Committee for Health Care Products (CEPS) and the Association of Pharmaceutical Industry (Les Entreprises du Médicament, LEEM) negotiate a price agreement for reimbursable pharmaceuticals in accordance with art. L 162-16-4 of the Social Security Code (CSS) or, if this is not possible, the Economic Committee for Health Care Products (CEPS) can set a price alone. This is carried out in accordance with the European Union (Union Européenne, EU) Transparency Directive. The Economic Committee for Health Care Products (CEPS) also conducts the economic regulation in the sector according to the advice received every year by the ministers concerned. The Economic Committee for Health Care Products (CEPS) is now involved in price setting for pharmaceuticals sold by hospitals to outpatients, as well as in tariff setting for costly products paid for directly by health insurance funds for inpatients in hospitals. The Economic Committee for Health Care Products (CEPS) is also involved in the regulation of medical visits by sales representatives of the pharmaceutical industry.

Decisions on reimbursement status are made by the Minister of Health and Social Affairs after receiving technical advice from a scientific committee, the Transparency Commission (Commission de la Transparence) which is a department of the French National Authority for Health (HAS), a new body created by the Law of 13 August 2004.
The new management of the health insurance system resulting from the 13 August 2004 reform is depicted in Figure 2.2.

**Figure 2.2: France - Health insurance organisation, 2006**

Source: CNAMTS
The new organisation for steering the health insurance system involves reinforced responsibilities, implemented through the steps described here.


a) Marked by the return of the employers’ representatives of the French Business Confederation (Mouvement des Entreprises Françaises, MEDEF) and the General Confederation of Small and Medium-sized Enterprises (Confédération Générale des Petites et Moyennes Entreprises, CGPME), and open to representatives of mutual insurance companies (cf. Section 1 Background) and other institutions in the health insurance sector, the Council consists of six members representing the Union Nationale des Professions Libérales (French National Union of Independent Professions), the Fédération Nationale des Travailleurs Handicapés (French National Union of Disabled Workers), the Union Nationale des Associations Familiales (French National Union of Family Associations), the Collectif inter-associatif sur la santé (Inter-Associative Health Group), the Union Nationale des Syndicats Autonomes (French National Union of Independent Trade Unions) and the Fonds de Financement de la CMUC (Fund for the Complementary Universal Health Insurance Coverage (CMUC), a means-tested, public supplementary insurance programme).

b) Set up to define the risk management policy guidelines and to clarify the modalities for implementing the health care policy and organisation of the health care system.

The creation of a French National Authority for Health (HAS):

a) as a body defining the scope of reimbursable treatments.

b) to conduct periodic evaluations of medical services and to draw up recommendations for good medical practices.

c) to conduct pharmaco-economic evaluations as of 2008.

d) to certify health websites, computer-assisted prescription softwares (2007)

A better representation of the health insurance system within the Economic Committee for Health Care Products (CEPS), which:

a) sets the prices of pharmaceuticals;

b) establishes the “Tarif forfaitaire de Responsabilité” (fixed amount on the basis of which Health Insurance Funds reimburse some groups of generic pharmaceuticals).

Different bodies are concerned with pharmaceuticals or similar products, e.g. the French Agency for the Medical Safety of Food Products (Agence Française de la Sécurité Sanitaire des Produits Alimentaires, AFSSA), the French Agency for Environmental Health and Safety (Agence Française de la Sécurité Sanitaire Environnementale et de Sécurité au Travail, AFSSSET) (with environmental problems and security at work), and the National Institute for Monitoring Public Health (Institut National de la Veille Sanitaire, INVS).
The decision on prescription status for a pharmaceutical is made by the Director of the French Health Products Safety Agency (AFSSAPS). It is a sanitary decision. Since Decree No. 2004-546 of 15 June 2005 under European Commission (EC) Directive 2001/83/EC on prescription status of pharmaceuticals, new forms of prescription status have been introduced in France. Now five classes of prescription status exist:

- pharmaceuticals used in hospital-only settings
- pharmaceuticals with hospital prescription
- pharmaceuticals with first hospital prescription
- pharmaceuticals with prescription reserved for certain specialists
- pharmaceuticals requiring a special monitoring during treatment.

The health insurance funds now manage the rate of reimbursement for each pharmaceutical and can modify the common rates for regulation, if this is necessary with certain limits (cf. section 4). They also sign a general agreement with doctors’ unions on the application of guidelines to increase economic efficiency in prescription and to promote prescription of generics (cf. chapter 5). They sign agreements with pharmacists to promote generic substitution (cf. section 5.5.1), participate in active risk management with sanitary missions, and also seek more effective regulation, e.g. on antibiotics consumption.

In mid-2003 the national health insurance fund (National Insurance Fund for Salaried Employees (CNAMTS) implemented health insurance representatives (Délégués d’Assurance Maladie, DAM), who were further developed according to the 2004 reform of the health care system. The objectives are to inform the health professionals on:

- the conventions signed with the health insurance fund;
- her/his activities;
- the insurance fund’s objectives and orientation of risk management.

The representatives conduct face-to-face visits with health professionals, who are mostly prescribing physicians, but also with pharmacists (e.g. on generic substitution) and dentists. A sample of professionals are targeted on specific themes e.g. antibiotics, generic substitution, breast cancer screening, prevention, overprescribing or unmet goals according to the conventions (i.e. conventions of the doctors with the health insurance fund). The duration of the visits is approximately 30 minutes with a target of 350,000 visits in 2008, so a health insurance representative (DAM) visits a general practitioner (Médecin Généraliste, GP) approximately three times per year. The workforce was approximately 950 in 2008 (700 in 2006). They are managed by a regional manager acting as the link between the National Insurance Fund for Salaried Employees (CNAMTS) and the health insurance representative (DAM). Health insurance representatives (DAM) are professionals with medical training specific to campaigns. Since 2007, they are certified by a Qualified Professional Certificate of the Social Security. Training accounted for approximately 25 days per health insurance representative (DAM) in 2006. Visit preparation consists of approximately one training day per campaign, including evaluation of the preparedness of the health insurance representative (DAM). They are provided with guidelines and spe-
specific documents to give to the professional, including a report on her/his activity. Impact evaluation has been conducted, for instance, a positive significant impact on prescription of antibiotics.

Table 2.1: France - Authorities in the regulatory framework in the pharmaceutical system, 2008

<table>
<thead>
<tr>
<th>Name in local language (Abbreviation)</th>
<th>Name in English</th>
<th>Description</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ministère des Affaires Sociales (MAS)</td>
<td>Ministry of Social Affairs</td>
<td>Regulatory body</td>
<td>Overall planning and legislative authority</td>
</tr>
<tr>
<td>Ministère de la Santé</td>
<td>Ministry of Health</td>
<td>In charge of the reimbursement legislation/decisions</td>
<td></td>
</tr>
<tr>
<td>Agence française de sécurité sanitaire des produits de santé (AFSSAPS)</td>
<td>French Health Products Safety Agency</td>
<td>Medicines agency (subordinate to the Ministry of Health)</td>
<td>In charge of market authorisation, classification, vigilance, advertisement</td>
</tr>
<tr>
<td>Haute Autorité de Santé (HAS)</td>
<td>French National Authority for Health</td>
<td>Independent body</td>
<td>Technical advice for including a pharmaceutical on the positive list; recommendations, pharmacoeconomic evaluations</td>
</tr>
<tr>
<td>Comité économique des produits de santé (CEPS)</td>
<td>Economic Committee for Health Care Products</td>
<td>Joint committee of ministers and health insurance funds</td>
<td>In charge of setting the prices of the reimbursable pharmaceuticals, some products in hospitals and the reference prices (TFR)</td>
</tr>
<tr>
<td>Union nationale des caisses d’assurance maladie (UNCAM)</td>
<td>National Union of Health Insurance Funds</td>
<td>Third party payers (Head of health insurance funds)</td>
<td>In charge of setting the (%) level for the reimbursement of pharmaceuticals</td>
</tr>
</tbody>
</table>

Source: CNAMTS

2.1.2 Pharmaceutical market

2.1.2.1 Availability of pharmaceuticals

On 1 January 2007 a total of 15,341 pharmaceuticals were registered in France (counting different pharmaceutical forms, dosages and pack sizes, but not including homeopathic products). All data presented are estimated based on many different partial sources. The French Health Products Safety Agency (AFSSAPS) is responsible for the different classifications of prescription-only medicines (POM) (Médicament à prescription obligatoire) and over-the-counter (OTC) pharmaceuticals or non-prescription products.
Table 2.2: France - Number of pharmaceuticals, 2000–2007

<table>
<thead>
<tr>
<th>Pharmaceuticals</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorised</td>
<td>11,470</td>
<td>12,140</td>
<td>12,780</td>
<td>13,340</td>
<td>14,110</td>
<td>14,990</td>
<td>14,391</td>
<td>15,341</td>
</tr>
<tr>
<td>On the market</td>
<td>6,640</td>
<td>7,060</td>
<td>7,500</td>
<td>7,910</td>
<td>8,280</td>
<td>8,650</td>
<td>9,448</td>
<td>9,714</td>
</tr>
<tr>
<td>POM</td>
<td>4,000</td>
<td>4,000</td>
<td>4,200</td>
<td>4,600</td>
<td>4,800</td>
<td>5,000</td>
<td>5,900</td>
<td>6,300</td>
</tr>
<tr>
<td>Reimbursable</td>
<td>5,100</td>
<td>5,100</td>
<td>5,200</td>
<td>5,500</td>
<td>5,700</td>
<td>6,100</td>
<td>6,610</td>
<td>6,981</td>
</tr>
<tr>
<td>Generics</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>1,240</td>
</tr>
<tr>
<td>Parallel traded</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>9</td>
</tr>
<tr>
<td>Hospital-only</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
</tbody>
</table>

POM = prescription-only medicine(s), n.a. = not available, n.s. = not significant

Source: CNAMTS, AFSSAPS

The increase of authorised pharmaceuticals between 2000 and 2007 is mainly due to new market authorisation of generics. However, the generics were not all marketed.

For reimbursable pharmaceuticals, the moderate increase is due to some de-listing.

Generic substitution has been allowed in France since 11 June 1999 (Art. L5125-23 of the Public Health Code (CSP) (for further information on generic promotion (cf. section 5.5.3). The French Health Products Safety Agency (AFSSAPS) monitors the positive list of generic products and establishes groups which contain the original product and its generics. Within each group, substitution by a pharmacist is possible. Certain substances which are not protected by licence are nonetheless not included in a group by the French Health Products Safety Agency (AFSSAPS), even though the law permits the creation of a group for these products, e.g. paracetamol or aspirin.

At the moment parallel imports are not significant in France. This market is quite limited and just beginning, with fewer than 10 market authorisations in 2007.

2.1.2.2 Consumption

Table 2.3: France – Annual prescriptions and consumption, 2000–2007

<table>
<thead>
<tr>
<th>Consumption</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of annual consumption in packs (billions)(^1)</td>
<td>3.01</td>
<td>3.04</td>
<td>3.05</td>
<td>3.08</td>
<td>3.05</td>
<td>3.12</td>
<td>3.03</td>
<td>n.a.</td>
</tr>
</tbody>
</table>

\(^1\) excluding hospital, n.a. = not available

Source: Leem from GERS
No data available on number of prescriptions. Data on consumption in DDD is only available for specific pharmaceutical classes, e.g:


2.1.2.3 Market data

The increase in the market is due mainly to the arrival of new products that are more costly than previously. The increase of the price per pack has a structural effect: an old cheap product is replaced by a new expensive one. In the hospital sector the increase is due to the arrival of very costly new products, e.g. those used in oncology.

Table 2.4: France - Market data, 2000–2006

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical sales</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales at ex-factory price level</td>
<td>14,635</td>
<td>15,626</td>
<td>16,311</td>
<td>17,320</td>
<td>18,360</td>
<td>19,438</td>
<td>19,762</td>
</tr>
<tr>
<td>Sales at wholesale price level</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Sales at PRP level</td>
<td>23,631</td>
<td>25,502</td>
<td>26,928</td>
<td>28,555</td>
<td>30,071</td>
<td>31,143</td>
<td>31,942</td>
</tr>
<tr>
<td>Sales in hospitals at ex-factory price level</td>
<td>2,628</td>
<td>3,049</td>
<td>3,600</td>
<td>4,000</td>
<td>4,400</td>
<td>4,400</td>
<td>4,591</td>
</tr>
<tr>
<td>Sales of generics at ex-factory price level, reimbursable market only</td>
<td>1,844</td>
<td>2,172</td>
<td>2,316</td>
<td>2,286</td>
<td>2,699</td>
<td>3,304</td>
<td>3,100</td>
</tr>
<tr>
<td>Sales of parallel traded pharmaceuticals</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Exports and imports at ex-factory price level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total pharmaceutical exports</td>
<td>9,621</td>
<td>12,861</td>
<td>14,467</td>
<td>14,529</td>
<td>15,340</td>
<td>16,747</td>
<td>18,081</td>
</tr>
<tr>
<td>Total pharmaceutical imports</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>10,589</td>
<td>11,921</td>
</tr>
</tbody>
</table>

n.app. = not applicable, n.a. = not available, PRP = pharmacy retail price

Source: LEEM from GERS (ex-factory price level excluding value-added tax (VAT)), *National health accounts 2005 - DREES (excluding hospital sales and including value-added tax (VAT))

The exports increased significantly thanks to the development of manufacturing activities. Many companies choose France for production. Since 1995, France is the most important exporting country in Europe for pharmaceuticals.

In terms of value, the generics market reached 17% of the reimbursable market in 2005, compared to 12.6% in 2000, but in terms of volume, generics accounted for 18.4% in 2000 and 25% in 2005 (for the generic market share in the outpatient sector cf. Table 5.1 in section 5.5).

Table 2.5: France - Top 10 best-selling pharmaceuticals, by active ingredient, 2006

<table>
<thead>
<tr>
<th>Position</th>
<th>Pharmaceutical, by active ingredient</th>
<th>Pharmaceutical, by active ingredient</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CLOPIDOGREL</td>
<td>PARACETAMOL</td>
</tr>
<tr>
<td>2</td>
<td>ATORVASTATINE</td>
<td>DEXTROPROPOXYPHENE + PARACETAMOL</td>
</tr>
<tr>
<td>3</td>
<td>PARACETAMOL</td>
<td>ACETYSALICYLIQUE ACIDE</td>
</tr>
<tr>
<td>4</td>
<td>PRAVASTATINE</td>
<td>AMOXICILLINE</td>
</tr>
<tr>
<td>5</td>
<td>OMEPRAZOLE</td>
<td>METFORMINE</td>
</tr>
<tr>
<td>6</td>
<td>SALMETEROL</td>
<td>LEVOTHYROXINE SODIQUE</td>
</tr>
<tr>
<td>7</td>
<td>ESOMEPRAZOLE</td>
<td>IBUPROFENE</td>
</tr>
<tr>
<td>8</td>
<td>ERYTROPOIETINE</td>
<td>PHLOROGLUCINOL</td>
</tr>
<tr>
<td>9</td>
<td>LANSOPRAZOLE</td>
<td>CODEINE IN ASSOCIATION</td>
</tr>
<tr>
<td>10</td>
<td>PANTOPRAZOLE</td>
<td>ZOLPIDEM</td>
</tr>
</tbody>
</table>

Source: MEDICAM CNAMTS14

2.1.2.4 Patents and data protection

In France, according to the European Patent Convention, original pharmaceuticals receive market protection for 20 years through the National Institute for Industrial Property (Institut National de la Propriété Industrielle, INPI) and under art. L 613-13 of the Intellectual Property Code (Code de la Propriété Intellectuelle, CPI). An additional period of five years maximum is possible with a Complementary Protection Certificate (Certificat Complémentaire de Protection, CCP). This certificate is attainable up to 15 years after the market authorisation; it is commonly accepted that the effective protection on the market is 15 years.

14 http://www.ameli.fr
### Table 2.6: France - Patent registration procedure

<table>
<thead>
<tr>
<th>Stage</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exploratory research</td>
<td>10 years</td>
</tr>
<tr>
<td>Pre-clinical tests</td>
<td></td>
</tr>
<tr>
<td>Clinical research</td>
<td>2-3 years</td>
</tr>
<tr>
<td>Administrative process</td>
<td></td>
</tr>
<tr>
<td>Marketing Pharmacovigilance</td>
<td></td>
</tr>
<tr>
<td>Patent application</td>
<td>5 years</td>
</tr>
<tr>
<td>Patent expiry</td>
<td>10 years</td>
</tr>
<tr>
<td></td>
<td>15 years</td>
</tr>
<tr>
<td></td>
<td>20 years</td>
</tr>
<tr>
<td></td>
<td>25 years</td>
</tr>
<tr>
<td></td>
<td>SPC max. + 5 yrs</td>
</tr>
</tbody>
</table>

R&D = Research and development  
*Source*: LEEM

### 2.1.3 Market players

This section describes the key players in the pharmaceutical system, apart from the authorities which have already been introduced. It gives an overview of the key players in production, distribution, dispensing, prescription and use of pharmaceuticals and their influence on pharmaceutical policy-making.

In the pharmaceutical distribution channels, the 337 manufacturers sell (cf. Figure 2.3):

- 14.3% of the total amount directly to 22,561 pharmacists;
- 67% to 11 wholesalers, of which 66.7% are sold to pharmacists and 0.4% to hospitals;
- 18.6% to hospitals.
2.1.3.1 Industry

There are 337 pharmaceutical companies based in France. They are all members of the Association of Pharmaceutical Industry (LEEM). This number includes 12 companies specialised in generics, members of the trade association Generic Producers Association (Association des Fabricants de Génériques, GEMME). Manufacturers specialised in non-reimbursable products are members of the French Association of Self-medication Industry (Association Francaise de l’Industrie Pharmaceutique pour une Automédication responsable, AFIPA). The French market is the third largest market in the world, with a market share of 5.6%.

The industry’s total sales were € 42,434 Mio. in 2006: domestic sales accounting for € 24,353 Mio. and exports € 18,081 Mio (source: LEEM). Domestic sales are broken down into € 18,265 Mio. of reimbursable products and € 1,497 Mio. of non-reimbursable products, which corresponds to a pharmacist market of € 19,762 Mio. in total. Hospital sales amount to € 4,591 Mio.

The industry employed 84,300 people in 1995 and 101,500 in 2005. Research employees represent 15% of the total workforce. France’s turnover is the highest in Europe. This industry is not so concentrated. The first five groups represent 34.5% of the total turnover and the first 10 represent 55%. The biggest manufacturer is Sanofi-Aventis with a market share of 15%, followed by Pfizer, Glaxo Smith Kline, Astra Zeneca and Bristol Myers Squibb.

In the generics business, the biggest company is Merck Generics (Merck AG Group), the second is BIOGARAN (Servier Group) and the third is Sandoz (Novartis Group).
At the moment parallel imports of pharmaceuticals represent very little in France. This market is just beginning, with fewer than 10 market authorisations in 2006. The administrative procedure is simplified, without any scientific study.

By advertising new pharmaceuticals categorised according to illness, the industry puts considerable pressure on health insurance funds.

One part of the industry makes the choice to enter into “nested” markets with only specialists to visit, or hospitals.

The industry struggles against health insurance funds in the generics market by introducing “me-too” products at the end of the patent for the original product, and by engaging in direct sales to pharmacists, with rebates/discounts (cf. section 3.6.1).

The industry is developing a new communicating approach to consumers by introducing discussion groups with patients, for instance to groups of patients concerned by rare diseases.

The pharmaceutical industry has a representative without voting rights in the Transparency Commission of HAS and is not represented in the Economic Committee for Health Care Products (CEPS).

The Association of Pharmaceutical Industry (LEEM) negotiates various agreements with the Economic Committee for Health Care Products (CEPS), e.g. a general agreement called an “accord cadre” regarding processes and means of regulation for outpatients. In March 2004, an “Accord Cadre Hôpital” was also signed between the Association of Pharmaceutical Industry (LEEM) and the Economic Committee for Health Care Products (CEPS) regarding pharmaceuticals sold to hospitals.

Since 1994, in order to contribute to an improvement in the long term on the economic environment, the State has wanted to initiate a convention (i.e. agreement) policy with the pharmaceutical industry.

Art. L 162-17.4 of the Social Security Code (CSS) creates the legal basis and support for this policy and has led to the “accord cadre” of the 13 June 1993 which has just been renewed, to be in effect until 2009 and modified by amendments No. 1 and No. 2 of the 29 January 2007 (cf. 3.1). These amendments confirm the method of pricing, the regulation via conventions, and contain 10 amendments.

The key issues of the general agreement (accord cadre) are listed here.

- It ensures the exchange of information and the monitoring of expenditure on reimbursable pharmaceuticals.
- It formalises the general measures for speeding up procedures and in particular for innovative pharmaceuticals (price notification, “dépôt de prix”).
- A whole chapter within the agreement is dedicated to the improvement of efficiency within pharmaceutical spending. It explains the framework of the agreements with the firms and defines those agreements (L 162-17-4 & L 158-10 from the Social Security Code (CSS), as well
as setting out the annual financial regulation and in particular the quantitative end of year discounts. Those discounts are made up of pharmacotherapeutic aggregate discounts and discounts on the turnover.

Amendment No. 2 has mainly modified the procedure of price notification ("dépôt de prix"). This procedure contributes to saving time: the Economic Committee for Health Care Products (CEPS), within the commitments submitted by the firm, has 15 days to oppose the price submitted, stating reasons as justification, or to accept it. The price has to be consistent with the price in Germany, Spain, Italy and the United Kingdom. Furthermore, financial compensation – if the sales forecasts are exceeded – and post-approval studies are planned.

At the time of writing, all products with a Level of improvement of clinical benefit (Amélioration du service médical rendu, ASMR, i.e. a rating on the level of improvement in the clinical benefit), I III (i.e. pharmaceuticals with a comparably high clinical benefit level) can benefit from this fast-track price notification procedure. Furthermore, products with the Level of improvement of clinical benefit (ASMR) IV can benefit from this procedure under certain conditions: there has to be a comparable pharmaceutical and the daily cost of treatment corresponding to the price submitted must be, at the most, equal to the comparator. The pharmaceutical is not intended to replace a generic.

The European price guarantee is maintained during the course of five years (an extension of one year is possible for paediatric pharmaceuticals).

Post-approval studies can be requested and whether or not the deadline has been respected will be examined.

The Economic Committee for Health Care Products (CEPS) will organise the manufacturers’ information when a generics manufacturer asks for the registration of a generic pharmaceutical.

For paediatric pharmaceuticals a price guarantee to an equivalent level of the daily cost of treatment for an adult must be obtained.

The Economic Committee for Health Care Products (CEPS) decides on the level of financial penalty in the event of an advertising ban.

A recent agreement, “Charte de la visite médicale”, has been signed between industry representatives (the Association of Pharmaceutical Industry (LEEM) and Economic Committee for Health Care Products (CEPS) on marketing methods used by sales representatives to inform doctors. Under this agreement, by proposal of the Ministry it is possible to choose some therapeutic classes for which the number of contacts between sales representatives and doctors must be reduced. In addition, there will be national procedures to qualify medical representatives.
Table 2.7: France – Key data on the pharmaceutical industry, 2000–2006

<table>
<thead>
<tr>
<th>Pharmaceutical industry</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total no. of companies</td>
<td>302</td>
<td>300</td>
<td>300</td>
<td>300</td>
<td>303</td>
<td>339</td>
<td>337</td>
</tr>
<tr>
<td>– research-oriented</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
</tr>
<tr>
<td>– generic producers</td>
<td>9</td>
<td>9</td>
<td>11</td>
<td>11</td>
<td>12</td>
<td>12</td>
<td>n.a</td>
</tr>
<tr>
<td>– biotech</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>300 (1)</td>
</tr>
<tr>
<td>Number of persons employed (2)</td>
<td>95,300</td>
<td>96,300</td>
<td>98,100</td>
<td>98,900</td>
<td>99,400</td>
<td>101,500</td>
<td>n.a</td>
</tr>
</tbody>
</table>

(2) counted per head

Source: Eco-Santé France 200815 - April 2008. (1) LEEM

2.1.3.2 Wholesalers

There are four leading wholesalers:
- OCP: approximately 40% market share with 52 outlets;
- Alliance Santé: approximately 29.5% market share with 57 outlets;
- CERP: approximately 26% market share with 71 outlets;
- Phoenix Pharma.

These wholesalers employ 15,400 people all over the country. Their role is critical in the distribution of pharmaceuticals (up to four deliveries a day, within a very short time). Altogether they store over 20,000 different packs. Each outlet delivers pharmaceuticals to an average number of 110 pharmacies, compared to 200 in Germany and in the United Kingdom.

Their activity is strictly controlled and under four legal obligations (art. R5124-59 of the Public Health Code (CSP):
- deliver pharmaceuticals to all pharmacies within their registered area of activity
- store at least 90% of existing pharmaceuticals
- keep a permanent stock equivalent to two weeks’ sales
- be able to supply any pharmaceutical to any pharmacist in the area within 24 hours.

In addition to the distribution of pharmaceuticals, they also provide various services, e.g.:
- information on pharmaceuticals (vocational training);
- assistance in pharmacy management and merchandising;
- legal information updates (laws, decrees, press reviews), and in particular, the French Health Products Safety Agency (AFSSAPS) alerts on faulty batches through web sites.

15 http://www.ecosante.org/
The wholesalers' trade association is called the Wholesalers Association (Chambre Syndicale de la Répartition Pharmaceutique, CSRP). They are not represented in the Economic Committee for Health Care Products (CEPS).

Wholesalers participate in the containment of health expenditure (HE) through a yearly contribution (between 1.9% and 2.5% of sales) to social security. The contribution in 2006 was € 268 Mio. for € 16,764 Mio. sales (source: CSRP).

Table 2.8: France - Key data on pharmaceutical wholesale, 2000–2006

<table>
<thead>
<tr>
<th>Wholesalers</th>
<th>2000¹</th>
<th>2001¹</th>
<th>2002¹</th>
<th>2003¹</th>
<th>2004¹</th>
<th>2005¹</th>
<th>2006¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total no. of wholesale</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>11</td>
<td>11</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>companies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of importers</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>2</td>
</tr>
<tr>
<td>Total no. of outlets</td>
<td>n.a</td>
<td>n.a</td>
<td>n.a</td>
<td>188</td>
<td>184</td>
<td>189</td>
<td>190</td>
</tr>
</tbody>
</table>

¹ as of 1 January, n.a. = not available

Source: CSRP

2.1.3.3 Pharmaceutical outlets / retailers

By law, pharmaceuticals in France are mostly sold through pharmacies which have de facto the monopoly. Drugstores and supermarkets are not allowed to sell pharmaceuticals and neither are Internet pharmacies.

Two other channels of distribution are possible, as described here.

- In some locations, a few doctors can sell pharmaceuticals (cf. section 2.1.3.3.4).
- Hospitals are also allowed to sell some pharmaceuticals to outpatients from a special positive list. These are treatments for severe conditions e.g. cancer, AIDS and hepatitis, for which the treatment has been initiated in hospital. The number of pharmaceuticals in this category tends to decrease as more and more become available from community pharmacies each month (cf. section 2.1.3.4).

2.1.3.3.1 Pharmacies

A pharmacist must be the owner of the pharmacy s/he runs and s/he must be a PharmD and a member of the Pharmacist professional board (Conseil National de l’Ordre, CNOP), and a French or European Union (EU) citizen. Pharmacists are allowed to own only one pharmacy, but since 1990 (Law 90-1258 of 31 December 1990) they have been allowed to have shares in other pharmacies.

The establishment of a new pharmacy is subject to a licence granted by the Préfet (local authority representing the State) after approval by the Pharmaceutical Association (CNOP) (art. L5125-1, -13, -14 and -15 of the Public Health Code (CSP). The authorisation is granted provided that the pharmacy fulfilled statutory demographic prerequisites as defined in the Public Health Code (CSP) (Art. L 5125-3, Art. L 5125-4). The rules as of 22 December 2007 are as follows:
• per 2,500 inhabitants for the first pharmacy;
• per 3,500 inhabitants for any additional pharmacy.

As of 22 December 2007 until 2010, no new pharmacy can be created, transfers being promoted instead. Transfers are authorised all over France during this period.

However, there is no particular incentive or obligation for pharmacists to establish pharmacies in rural areas. In remote places, where a pharmacy would not be financially viable, access to pharmaceuticals is ensured by dispensing doctors (122 in total). The total number of private community pharmacies as of 2006 was 22,651 (cf. Table 2.9), i.e. one pharmacy per 2,700 inhabitants.

Ownership of pharmacies is only allowed by pharmacists. Branch pharmacies are not permitted, but pharmacies can be run as incorporated companies, known as Sociétés d’Exercice Libéral (SEL) so a pharmacist can invest in a share of another pharmacy.

Opening hours, number of pharmacists employed, availability of pharmaceuticals by wholesalers and advertising are also regulated.

Internet pharmacies are not allowed in France. Pharmaceuticals can only be purchased from non-French web sites. It is legal for consumers to purchase over-the-counter (OTC) pharmaceuticals from foreign Internet pharmacies. However, the Pharmaceutical Association (CNOP) is currently looking into this problem and trying to work out how to legalise this business.

Pharmacists can purchase pharmaceuticals directly from the manufacturer, especially products with a high turnover. Discounts granted to pharmacists by wholesalers or the pharmaceutical industry are regulated.

The majority of pharmacies are privately owned but there are a few “mutuelles” (i.e. complementary health insurance)-owned pharmacies. Pharmacy chains are not allowed but pharmacies are allowed to belong to groups of pharmacies (there are approximately 40 of them) with common interests (in purchasing, merchandising, advertising, etc.). In France, four types of pharmacies exist, as detailed here.

• Private pharmacies, owned by a pharmacist, represent the majority of pharmacies. There have been fewer than approximately 23,000 since the year 2000.
• Pharmacies that are part of the mining social insurance scheme which only miners from this scheme can access. By law, miners can go to private or “mutual” pharmacies but don’t do so in practice since they would have to pay in advance for their pharmaceuticals. They are owned by the mining health insurance fund so pharmacists are managers and employees.
• Few “Mutual” pharmacies are accessible to all patients covered by a complementary mutual health insurance association (cf. section 2.2). They are owned by the union of mutuals “La Mutualité Française”, which means that pharmacists are managers and employees.
• Hospital pharmacies for outpatients also exist.
Table 2.9: France - Retailers of pharmaceuticals, 2000–2007

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of community pharmacies</td>
<td>22,839</td>
<td>22,868</td>
<td>22,835</td>
<td>22,829</td>
<td>22,794</td>
<td>22,747</td>
<td>22,697</td>
<td>n.a.</td>
</tr>
<tr>
<td>No. of private pharmacies</td>
<td>22,698</td>
<td>22,727</td>
<td>22,697</td>
<td>22,691</td>
<td>22,658</td>
<td>22,610</td>
<td>22,561</td>
<td>22,516</td>
</tr>
<tr>
<td>No. of pharmacies of the mining scheme 1</td>
<td>68</td>
<td>68</td>
<td>68</td>
<td>68</td>
<td>69</td>
<td>68</td>
<td>68</td>
<td>n.a.</td>
</tr>
<tr>
<td>No. of mutual pharmacies</td>
<td>73</td>
<td>73</td>
<td>70</td>
<td>70</td>
<td>68</td>
<td>68</td>
<td>68</td>
<td>n.a.</td>
</tr>
<tr>
<td>No. of public pharmacies</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
</tr>
<tr>
<td>No. of hospital pharmacies for outpatients</td>
<td>n.a.</td>
<td>n.a.</td>
<td>1,575</td>
<td>1,569</td>
<td>1,561</td>
<td>1,551</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>No. of other POM dispensaries: SD doctors</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>122</td>
<td>122</td>
<td>n.a.</td>
</tr>
<tr>
<td>Total no. of POM dispensaries</td>
<td>22,839</td>
<td>22,868</td>
<td>24,410</td>
<td>24,398</td>
<td>24,355</td>
<td>24,420</td>
<td>22,819</td>
<td>n.a.</td>
</tr>
<tr>
<td>No. of Internet pharmacies</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
</tr>
<tr>
<td>No. of OTC dispensaries, e.g. drugstores:</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
<td>n.app.</td>
</tr>
</tbody>
</table>

n.a. = not available, n.app. = not applicable, OTC = over-the-counter (pharmaceuticals), POM = prescription-only medicine(s), POM dispensaries = including SD doctors and hospital pharmacies for outpatients acting as community pharmacies

1 as of 31 December, SD = self-dispensing

Source: Eco-Santé France 2007\textsuperscript{16}, IRDES. 2007 number of private pharmacies: CNOP\textsuperscript{17}


\textsuperscript{17} [http://www.ordre.pharmacien.fr/fr/bleu/index3.htm](http://www.ordre.pharmacien.fr/fr/bleu/index3.htm)
Pharmacists may belong to a trade association, as listed here.

- Federation of Pharmacists in France (Fédération des Syndicats Pharmaceutiques de France, FSPF).
- National Union of Pharmacists of France (Union Nationale des Pharmacies de France, UNPF).
- Union of Pharmacists (Union des Syndicats de Pharmaciens d’Officine, USPO).
- Federation of Rural Pharmacies (Association des Pharmacies Rurales, APR).

The trade associations are represented in negotiations with the health insurance authorities. They are also involved in the licensing process with the local authorities and pharmaceutical associations.

Pharmacists’ remuneration is a combination of profit margin and a flat fee per pack (cf. Table 3.5). Details are given here:

- for ex-factory price < € 22.90, the margin is 26.1% of ex-factory price
- for ex-factory price from € 22.91 to € 150.00, the margin is 10.0%
- For ex-factory price > € 150.00, the margin is 6.0%
- + an additional € 0.53 fee per pack.

For further details cf. section 3.5.2.

Source: Eco-Santé France 2007\textsuperscript{18}, IRDES

\textsuperscript{18} http://www.ecosante.fr/index.php?langs=FRA&langh=FRA&sessionid=
2.1.3.3.2 Other pharmacy outlets
Not applicable.

2.1.3.3.3 Internet pharmacies
There are no French-based Internet pharmacies, but pharmaceuticals are available from non-French Internet pharmacies. However, the Pharmaceutical Association (CNOP) is currently looking into this issue and trying to work out how to legalise and control this channel of distribution.

2.1.3.3.4 Dispensing doctors
In some remote areas authorised doctors can dispense pharmaceuticals. This is the case on some small islands, in some mountain valleys and some rural areas. The total number of dispensing doctors is 122.

Midwives and physiotherapists are allowed to prescribe a limited number of pharmaceuticals but not to dispense them.

2.1.3.4 Hospitals
Hospital pharmacies (pharmacies à usage intérieures, PUI) dispense pharmaceuticals to inpatients as well as to outpatients. Although all hospitals dispense pharmaceuticals to inpatients, only a number of them dispense pharmaceuticals to outpatients. It is each hospital’s decision. Only public hospitals are allowed to dispense pharmaceuticals to outpatients; private hospitals are not.

Hospital pharmacies are allowed to dispense pharmaceuticals from a special list for outpatients. The number of hospital-only medicines (Médicament de la réserve hospitalière, HOM) dispensed to outpatients tends to decrease as more and more become available from community pharmacies. In fact, hospitals choose to work with a limited list of pharmaceuticals. The list is drawn up by a Hospital Committee (one in each hospital, whether public or private) from a special list of pharmaceuticals approved for hospital use. Usefulness within the hospital, improvement of medical service provided, as well as economic criteria are all taken into account when deciding whether to include a pharmaceutical in the hospital’s list.

The composition and operating mode of Hospital Committees are regulated (Decree No. 2000-1316 of 26/12/2000, Art. 5104-52 to 56). There are currently three main purchasing procedures, explained here.

- At standard price, upon invoice (used only marginally).
- Negotiations with the manufacturer.
- Public tendering for equivalent pharmaceuticals, according to forecasted volumes (approximately 60% of hospital purchases). The final decision is not necessarily in favour of the cheaper supplier, but rather in favour of the supplier who is most likely to ensure continuous supply, to avoid shortage.

Based on Decree No. 2006-975 of 1 August 2006, a national tendering procedure is to be implemented for public hospitals.
Some public hospitals in the same geographical area already belong to bulk-buying organisations. This is the same with private hospitals.

The pharmaceutical lobbies put a lot of pressure on the younger hospital doctors in particular, in order to persuade them to include new pharmaceuticals in the hospital's list, as a way of enhancing primary care prescribing.

Hospital pharmacies are funded mostly out of the hospital budget. The cost of the pharmaceuticals is included in the inpatient's daily fee, based on diagnosis related groups (DRGs). However, prices are regulated for a number of highly innovative and costly pharmaceuticals, for which the hospital can claim reimbursement from the Health Insurance Funds for inpatients.

2.1.3.5 Doctors

The principal unions of doctors are:

- for generalists, the French Federation of General Practitioners (Fédération française des médecins généralistes, MG FRANCE), the Confederation of French Medical Unions (Confédération des Syndicats Médicaux Français, CSMF), the Federation of Doctors in France (Fédération des Médecins de France, FMF) and the Union of Self-employed Doctors (Syndicat des Médecins Libéraux, SML);

- and for specialists, the Confederation of French Medical Unions (CSMF). They are represented in some committees, e.g. the group that enters into discussions with the Economic Committee for Health Care Products (CEPS) on generics.

The unions sign an agreement with health insurance funds. The latest one was signed on 12 January 2005 between the National Union of Health Insurance Funds (UNCAM) and the Union of Self-employed Doctors (SML), the Confederation of French Medical Unions (CSMF) and ALLIANCE. It was published in the official bulletin on 11 February 2005. This new agreement is unique for general practitioners (GPs) and specialists. In return for higher tariffs, doctors accept a new organisation of the system with the introduction of a sort of "gatekeeper" role, being the "médecin traitant", as the standard way to consult. S/He can refer the patient to a specialist as the "médecin correspondant".

This agreement promotes guidelines for rational use of pharmaceuticals in the activities of doctors and determines targets on the use of pharmaceuticals and on savings in some therapeutic areas, including antibiotics, statins, proton pump inhibitors (PPI) and generics. This includes good practices and cost-effective prescribing. There are no direct penalties (cf. section 5.2 for further details).

2.1.3.6 Patients

Retail prices for reimbursable pharmaceuticals are in fact the same in all pharmacies, but differences in price exist for non-reimbursable pharmaceuticals. Few patients' lobbies influence pharmaceutical policy on pricing in the reimbursed pharmaceutical sector for chronic diseases, especially in the scope of rare diseases, HIV etc.. However, groups of patients are lobbying with the French Health Products Safety Agency (AFSSAPS) regarding treatments for specific dis-
eases or to obtain rapid access for orphan pharmaceuticals or for special products with temporary utilisation authorisation (ATU) status.

Since the introduction of the Law of 13 August 2004, a patient must choose a “médecin traitant”, a doctor of first choice. If s/he refuses to do so, reimbursement will be decreased by 10%.

Since 1 January 2008, patients have to pay fixed co-payments:

- € 0.5 per pharmaceutical pack purchased;
- € 1 per visit or consultation of the prescriber.

2.2 Funding

This section provides an overview of the funding of pharmaceuticals. This includes pharmaceutical expenditure (PE) and the allocation of funds for pharmaceuticals.

2.2.1 Pharmaceutical expenditure

The French pharmaceutical expenditure (PE) accounted for € 31,942 Mio. in 2006. It increased significantly (+29%) from 2000 to 2005 (4.4% annual growth rate). Per inhabitant, it amounted to € 521 in 2006 compared to 427 in 2000, a rise at an annual pace of 3.8%. This significant increase is partly explained by the structural effect of the pharmaceutical sector; medical progress and the fact that new pharmaceuticals are increasingly more expensive. Consumption volumes are also responsible, to a lesser extent, despite incentives to limit them.

From 2000 to 2005, the share of public pharmaceutical expenditure (PE) in total health expenditure (Dépenses totales de santé, THE) rose from 12.4% to 11.3%, whereas the share of private pharmaceutical expenditure (PE) decreased by less than 1% (from 5.9% to 5.1%).
Table 2.10: France - Total pharmaceutical expenditure, 2000–2007

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TPE as a % of THE</td>
<td>18.2</td>
<td>18.8</td>
<td>18.7</td>
<td>16.5</td>
<td>16.6</td>
<td>16.4</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>TPE per capita in €</td>
<td>427</td>
<td>461</td>
<td>486</td>
<td>476</td>
<td>500</td>
<td>515</td>
<td>521</td>
<td>n.a.</td>
</tr>
<tr>
<td>Public PE as a % of THE</td>
<td>12.4</td>
<td>13.0</td>
<td>13.1</td>
<td>11.3</td>
<td>11.4</td>
<td>11.3</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Private PE as a % of THE</td>
<td>5.9</td>
<td>5.8</td>
<td>5.7</td>
<td>5.2</td>
<td>5.2</td>
<td>5.1</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
</tbody>
</table>

N.a. = not available, PE = pharmaceutical expenditure, THE = total health expenditure, TPE = total pharmaceutical expenditure,

Source: OECD Health Data 2007, National Health Accounts 2006

2.2.2 Sources of funds

The financing of statutory health insurance varies from scheme to scheme. The financing of social security in general, and of health insurance in particular, depends on two main sources:

- social contributions (46% of the funding) based on earnings from employees, employers and those on benefits (retired people, those on early retirement benefit and unemployed people) as a proportion of wages and salaries;
- taxes (45%) including
  - mainly (34%) the “general social contribution” (contribution sociale généralisée, CSG) based on total income (the general social contribution (CSG) rate varies depending on the source of income;
  - other taxes: 11.4%;
- and other sources of funding: 9.1%, including state contribution and transfers.

Public pharmaceutical expenditure (PE) (social security and state or local funds) accounted for 69% of the outpatient pharmaceutical expenditure (PE) in 2006. The remaining 31% from private expenditure included 19% of expenses for private health insurance and 12% of out-of-pocket payments (OPP) (including cost-sharing and self-medication) of households.

Private health insurance in France corresponds to complementary health insurance which patients subscribe to on a (usually) voluntary basis. In 2006, a total of 93% of the population is covered by complementary health insurance, including 4% covered by the free Complementary Universal Health Insurance Coverage (CMUC), provided for people with low incomes.

20 Source: IRDES, ESPS survey: http://www.irdes.fr/EspaceRecherche/Enquetes/ESPS/EnqueteESPS.html
In France, there are three types of complementary health insurers:

- mutual insurance associations ("mutuelles");
- private insurance companies;
- provident institutions, co-managed by representatives of employers and employees.

The mutual insurance associations (cf. chapter 1 Background) play a dominant role in providing complementary health insurance coverage, financing 12% of total pharmaceutical expenditure (TPE), while private insurance companies account for 4%, and the provident institutions for 2.5%.

For the most part, employees do not subscribe on a voluntary basis in the context of employment, where the employer/professional organisation enters into a collective (group) contract with an insurance provider on behalf of all its employees or a specific professional group. A total of 44% of employees are covered by a complementary health insurance scheme subscribed by their employers and 32% subscribe to one individually on a voluntary basis (cf. section 4.4).²¹

Self-medication, defined as pharmaceuticals bought without a medical prescription, represented 6% of the pharmaceutical sales in France in 2007 (13% in volume), accounting for € 1.9 billion.²² At pharmacy retail price (Prix à la consommation ou prix public, PRP) level, including value-added tax (Taxe sur la Valeur Ajoutée, VAT), the Association of the European Self-Medication Industry (AEGSP) estimated self-medication to be at € 1.99 billion in 2006.

In 2006, non-reimbursed prescribed pharmaceuticals accounted for 3% of the pharmaceutical market.

---

²¹ Workplace provided supplementary health insurance, Health economics letter 115, IRDES 2006)
²² AFIPA: http://afipa.org/index/informations,cp_afipa_14-02-08.pdf
Figure 2.5: France - Share of private and public outpatient pharmaceutical expenditure, 2006

Source: CNAMTS from DREES, National Health Accounts 2006\textsuperscript{23}

\textsuperscript{23} National health accounts: http://www.sante.gouv.fr/drees/cptsante/cns2006.htm
3 Pricing

3.1 Organisation

After having obtained market authorisation, the manufacturer can decide on which market to place the pharmaceutical. A key distinction is on the hospital market for inpatients and the market for outpatients who buy pharmaceuticals in pharmacies (cf. Table 3.1). For the hospital market pricing is free.

For the outpatient market, the manufacturer can choose to enter the non-reimbursable market or the reimbursable market. If s/he chooses the non-reimbursable market, pricing is totally free and s/he can sell the product the day after having obtained the market authorisation. If s/he chooses the reimbursable market, the price is regulated and the process for getting granted reimbursement status is regulated.

The Pricing Committee (Economic Committee for Health Care Products, CEPS) is in charge of pricing reimbursable pharmaceuticals only. There is free pricing for non-reimbursable pharmaceuticals. The Economic Committee for Health Care Products (CEPS) needs the advice of the Transparency Commission for setting the price. This advice contains a Level of clinical benefit ("Service medical rendu", SMR), which may be considered as major, moderate, weak or insufficient, and a Level of improvement of clinical benefit (ASMR) against the comparable products existing in the market, from ASMR 1 to ASMR 5 (cf. section 4.1).

As a rule, the Economic Committee for Health Care Products (CEPS) finds an agreement with the manufacturer on the price in line with the technical level of relative improvement provided by the product in comparison with other products available in the same therapeutic area. Very seldom, there is no agreement with the manufacturers. In such cases the product is not entered into the positive list. It is always possible for manufacturers to decide to reopen the discussion on a new basis.

The members of the Committee (that holds a weekly meeting) with voting rights are:

- President (Independent expert – s/he must try to find a consensus between members);
- Vice President (Independent expert);
- one representative of the Ministry of Social Affairs (MAS);
- one representative of the Ministry of Health;
- one representative of the Ministry of Industry;
- one representative of the Ministry of Finance;
- two representatives of the health insurance fund for salaried people;
- one representative for other health insurance funds;
- one representative for complementary insurance and private insurance;
• two members without voting rights – one representative of the Directorate of Hospitals in the Ministry of Social Affairs (MAS) and one representative of the Ministry of Research.

For a reimbursable product, a report is submitted simultaneously to the French National Authority for Health (HAS) for technical advice from the Transparency Commission, to the Economic Committee for Health Care Products (CEPS) for pricing, and to the National Union of Health Insurance Funds (UNCAM) for the reimbursement rate.

The time frame for inclusion on the positive list and decisions on pricing and the level of reimbursement complies with the timing of the Transparency Directive (180 days). At the end of the process, the Ministry of Social Affairs' (MAS) decision regarding the inclusion of the product on the positive list, the price granted by Economic Committee for Health Care Products (CEPS) and the reimbursement rate granted by the National Union of Health Insurance Funds (UNCAM) are all published in the same issue of the country's official bulletin.

There is a 3-year plan to reduce prices, in order to reduce the total reimbursement amount (cf. section 3.6.4).

### 3.2 Pricing policies

France was one of the first countries to exhibit real transparency on prices for more than 20 years, with a public database that every patient can consult. This service is now on the Internet websites of health insurance funds.\(^{24}\)

**Table 3.1: France - Ways of pricing pharmaceuticals, 2008**

<table>
<thead>
<tr>
<th></th>
<th>Manufacturer Level</th>
<th>Wholesale Level</th>
<th>Pharmacy Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free pricing</td>
<td>Free pricing for all non-reimbursable pharmaceuticals in outpatient care</td>
<td>Free pricing as well for almost all products on the hospital positive list</td>
<td>Free pricing for non-reimbursable pharmaceuticals</td>
</tr>
<tr>
<td>Statutory pricing</td>
<td>Controlled for reimbursable pharmaceuticals</td>
<td>Regressive mark up scheme for wholesalers for reimbursable pharmaceuticals</td>
<td>Reimbursable pharmaceuticals via a regressive mark up scheme, which can be reviewed by the Minister</td>
</tr>
<tr>
<td>Price negotiations</td>
<td>Between manufacturers and CEPS</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Discounts / rebates</td>
<td>Yes, for sales volumes exceeding negotiated sales forecasts</td>
<td>Possible by decree, with certain limits</td>
<td>Possible but in fact not used</td>
</tr>
<tr>
<td>Public procurement</td>
<td>cf. section 3.2.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 3.2.1 Statutory pricing

For products listed on a positive list and available from community pharmacies, the ex-factory price and wholesalers’ and pharmacists’ margins are regulated. The ex-factory price, excluding value-added tax (VAT), and the pharmacy retail price (PRP), including value-added tax (VAT) (including wholesalers’ and pharmacists’ margins), are published in the country’s official bulletin.

Since 2004, pharmaceuticals for outpatients only available from hospital pharmacies have been controlled. At ex-factory level, the margin is controlled as well. The price is negotiated between the Economic Committee for Health Care Products (CEPS) and the manufacturer. If an agreement cannot be reached, the price can be set by the Economic Committee for Health Care Products (CEPS).

The negotiations are carried out in compliance with a procedure described in a general agreement between the industry and the Economic Committee for Health Care Products (CEPS) ("accord cadre"), the duration of which is four years. This concerns all reimbursable pharmaceuticals, at all price levels. A new agreement was signed at the beginning of 2007.

### 3.2.2 Negotiations

As a rule, the Economic Committee for Health Care Products (CEPS) finds an agreement with the manufacturer on the price in line with the technical level of relative improvement provided by the product in comparison with other products available in the same therapeutic area. Very seldom, there is no agreement with the manufacturers. In such cases the product is not entered into the positive list. It is always possible for manufacturers to decide to reopen the discussion on a new basis.

Since 2004, pharmaceuticals for outpatients only available from hospital pharmacies have been controlled. At ex-factory level, the margin is controlled as well. The price is negotiated between the Economic Committee for Health Care Products (CEPS) and the manufacturer. If an agree-
ment cannot be reached, the price can be set by the Economic Committee for Health Care Products (CEPS).

The negotiations are carried out in compliance with a procedure described in a general agreement between the industry and the Economic Committee for Health Care Products (CEPS) (“accord cadre”), the duration of which is four years. This concerns all reimbursable pharmaceuticals, at all price levels. A new agreement was signed at the beginning of 2007.

3.2.3 Free pricing

Non-reimbursable pharmaceuticals in the outpatient sector have benefited from free pricing at all levels since 1986, according to an edict that cancels the general price control in France. This is the same for pharmaceuticals purchased by hospitals.

3.2.4 Public procurement / tendering

A tendering procedure exists for pharmaceuticals with alternatives purchased by hospitals (e.g. generics). In the public procurement procedure, favourable prices offered are an important criterion in the decision process.

3.3 Pricing procedures

The pricing procedure in France is a mixture of internal price referencing and external price referencing, as described in Table 3.2.

<table>
<thead>
<tr>
<th>Pricing procedure</th>
<th>In use: Yes / no</th>
<th>Level of pricing</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal price referencing</td>
<td>Yes</td>
<td>Ex-factory price</td>
<td>Reimbursable pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wholesaler's mark up</td>
<td>Retrocession = Hospital outpatient prescribing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacist's mark up</td>
<td>The comparison with the prices of other products is systematically performed for all reimbursable pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Internal price referencing is only carried out at ex-factory price level; the margins are then added according to the regulations</td>
<td></td>
</tr>
<tr>
<td>External price referencing</td>
<td>Yes</td>
<td>Ex-factory price</td>
<td>Part of reimbursable pharmaceuticals: those with the highest level of improvement of medical service (reference countries are United Kingdom, Germany, Italy, Spain)</td>
</tr>
<tr>
<td>Cost-plus pricing</td>
<td>No</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
In French law, the process of external price referencing is described in Art. L-162-17-6 of the Social Security Code (CSS). In the “accord cadre” 2003-2006, Art. 4 describes the procedure for setting the pricing process for innovative products. For these products, the principle is that the price is fixed within 14 days after receiving the advice of the Transparency Commission.

A prerequisite is that the pharmaceutical company has signed an agreement, a “convention” of four years’ duration with the Economic Committee for Health Care Products (CEPS) under Art. L 162-17-4 of the Social Security Code (CSS).

For this to be applicable to a product, the procedure requires that:

- the product has a Level of improvement of clinical benefit (ASMR) I, II or III for the major indication; or
- the product has a Level of improvement of clinical benefit (ASMR) IV in specific cases for some level of daily cost of comparable products and if the product will not replace an existing product with generics.

The company must apply for a price similar to the price accepted by the company in Germany, Spain, Italy and the United Kingdom (the information on these prices is provided directly by the company). The company also agrees that all price changes in these other countries will be reflected by a price change in France, and signs an agreement on the volume of the sales. If that agreement is not respected, the company must pay a claw-back payment (cf. section 4.6.4). As a symbol of “goodwill”, the company may sign additional agreements with the Economic Committee for Health Care Products (CEPS), e.g. agreeing that it will recommend the posology that is proposed in the summary of product characteristics (SPC) and also pragmatic studies on the use of the product in “real life”.

---

3.3.2 Internal price referencing

Comparisons in prices are systematically carried out for all reimbursable pharmaceuticals with the indications mentioned by the Transparency Commission in the advice given on the pharmaceutical. Generally, comparisons are made using daily cost of treatment, or sometimes using the cost of a “cure” (i.e. the cost of the therapies when used at the recommended dose level for the recommended duration). Comparisons are made primarily on ex-factory prices and for each strength and each pack size.

3.3.3 Cost-plus pricing

Not applicable.

3.3.4 (Indirect) Profit control

Not applicable.

3.4 Exceptions

3.4.1 Hospitals-only medicines

Most hospital pharmaceuticals are freely priced. There is, however, a list of particularly innovative pharmaceuticals for which prices are regulated. Hospitals carry out their own procurement, either through negotiations with the pharmaceutical industry, or through tendering. Some hospitals, usually operating in the same geographical area, group together in bulk-buying organisations to negotiate cheaper purchase prices. In 2007 a public tendering procedure will gradually be implemented at national level for public hospitals. The prices granted by the pharmaceutical companies are significantly lower than those in the outpatient sector. It is up to each hospital to decide whether they want to publish their prices. Communication on prices is not compulsory.

3.4.2 Generics

Two types of incentives exist for the pricing of generics:

- If a generics manufacturer requests a price in line with the rate of difference in price of the patented original product (a specific percentage lower), they are sure to obtain this price and the pharmaceutical will be placed in the reimbursement list without delay.

- For a pharmacist, there is no difference in delivering a generic or the equivalent brand name product. By law the pharmacist earns the same amount of money in absolute figures when dispensing a generic as when dispensing the original product (cf. section 3.5.2).

To calculate the ex-factory price of a generic of an original product, the ex-factory price of the original product is multiplied by 0.6 (until the year 2005) and by 0.5 (from 2006 onwards). The pharmacy retail price (PRP) is the sum of the ex-factory price plus the wholesale mark up plus the pharmacist's mark up, which is the same for the original product. In application of the Minis-
terial Order of 8 August 2003, the pharmacy retail price (PRP) of a generic is calculated as the sum of the ex-factory price plus the wholesale margin plus the pharmacist's margin, which is the same for the original product (except for pharmaceuticals under the reference price system, called TFR, cf. section 3.9.1).

**3.4.3 Over-The-Counter pharmaceuticals**

In France before 2008, Over-the-counter (OTC) pharmaceuticals did not exist since no pharmaceuticals were on free access including non-reimbursable pharmaceuticals. Since 1 July 2008, the government approved the free access for consumers of a specific list of non-reimbursable pharmaceuticals in pharmacies. The list\(^\text{26}\) of 217 pharmaceuticals was published by the Ministry of Health.

In France, OTC as non-reimbursable pharmaceuticals are freely priced. The wholesalers' and pharmacists' margins are also free. Over-the-counter (OTC) pharmaceuticals are not reimbursed, but in certain therapeutic classes they are in direct competition with reimbursable products. This situation limits the growth of the over-the-counter (OTC) market because reimbursable products are always cheaper.

**3.4.4 Parallel traded pharmaceuticals**

The pricing system for parallel traded pharmaceuticals has been the same as for other pharmaceuticals in France since the integration of the relevant European legislation by Decree No. 2004-83 of 23 January 2004. Only 9 products are approved.

**3.4.5 Other exceptions**

To the authors' knowledge there are no other exceptions.

**3.5 Margins and taxes**

This section contains a description of the wholesale and pharmacy margins and mark ups, dispensing fees and sales taxes applied to pharmaceuticals.

The margin system is different for reimbursable and non-reimbursable products as well as for outpatients and inpatients buying pharmaceuticals from a hospital pharmacy.

For non-reimbursable products, prices and margins are freely established. In March 2008 an agreement was signed between industry and pharmacists for good practices on pricing for products just delisted from reimbursable positive list.

For reimbursable products, margins are controlled for wholesalers and pharmacists. For outpatient and reimbursable pharmaceuticals a regressive mark up scheme is now in place.

For hospital pharmaceuticals dispensed to outpatients in hospital pharmacies a fixed fee is applied. The legal basis defining the rules for wholesalers’ and pharmacists’ margins for reimbursable pharmaceuticals has been the same Ministerial Order for many years. Before 1990 this was worked out based on a proportion of the ex-factory price.

From 2 January 1990 a regressive mark up scheme was in place for pharmacies. This regulation changed on 28 April 1999 with the introduction of a fixed fee per pack for pharmacists, and on 12 February 2004 it changed again to three levels, officially published on 21 February 2004.

Table 3.3: France - Regulation of wholesale and pharmacy mark ups, 2008

<table>
<thead>
<tr>
<th>Wholesale mark up</th>
<th>Pharmacy mark up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulation (yes / no)</td>
<td>Content</td>
</tr>
<tr>
<td>France</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*Scope = a pricing procedure does not always refer to all pharmaceuticals: e.g. a pricing procedure could only refer to reimbursable pharmaceuticals, whereas for over-the-counter (OTC) pharmaceuticals there is free pricing.

Source: CNAMTS

Table 3.4: France - Structure covered by social insurance, i.e. for reimbursable pharmaceuticals

<table>
<thead>
<tr>
<th>Country</th>
<th>Ex-factory price</th>
<th>% Wholesaler’s margin</th>
<th>Controlled price</th>
<th>% Pharmacist’s margin</th>
<th>% Value-added tax (VAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>Published</td>
<td>For ex-factory price (excluding VAT) ranging from: € 0-22.90: 9.93% € 22.91-150.00: 6.0% € 150.00-400: 2.0% &gt;€ 400: 0%</td>
<td>Ex-factory price excluding VAT Wholesaler margin Pharmacist’s margin Pharmacist’s price including VAT</td>
<td>For ex-factory price (excluding VAT) ranging from: € 0-22.90: 26.1% € 22.91-150.00: 10.0% &gt;€ 150.00: 6 % + a flat fee of € 0.53 excluding VAT per pack Specific margin for generics not under reference price: based on the price of the original product</td>
<td>2.1</td>
</tr>
</tbody>
</table>

Source: CNAMTS
3.5.1 Wholesale remuneration

Wholesale margins are regulated for reimbursable pharmaceuticals. These are remunerated through a regressive mark up scheme, regulated by means of a Ministerial Order signed by the Ministry of Health and the Ministry of Finance. The latest amendment was on 6 March 2008 (official bulletin27).

Table 3.5: France - Wholesale mark up scheme for reimbursable pharmaceuticals, 2008

<table>
<thead>
<tr>
<th>Ex-factory price in € (excluding value-added tax (VAT))</th>
<th>Maximum mark up as a % of ex-factory price</th>
<th>Wholesale price in € (excluding VAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.00-22.90 example 22.90</td>
<td>9.93</td>
<td>25.17</td>
</tr>
<tr>
<td>22.91-150.00 example 150.00</td>
<td>6.0</td>
<td>159.90</td>
</tr>
<tr>
<td>150.00-400 example 400</td>
<td>2.0</td>
<td>414.90</td>
</tr>
<tr>
<td>&gt; 400 example 1,000</td>
<td>0</td>
<td>1,014.90</td>
</tr>
</tbody>
</table>


3.5.2 Pharmacy remuneration

Pharmacists’ unions indicated an average margin on reimbursable pharmaceuticals of 24% in 2001 and 23.8% in 2004. If the rate goes down, the total amount continues to increase with the growth of the turnover.

Table 3.6: France - Pharmacy mark up scheme for reimbursable pharmaceuticals, 2008

<table>
<thead>
<tr>
<th>Ex-factory price in € (excluding value-added tax (VAT))</th>
<th>Maximum mark up in % of ex-factory price + € 0.53 per pack excluding VAT</th>
<th>Public price in € excluding VAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.00-22.90 example 22.90</td>
<td>26.1</td>
<td>31.68</td>
</tr>
<tr>
<td>22.91-150.00 example 150</td>
<td>10.0</td>
<td>179.12</td>
</tr>
<tr>
<td>&gt; 150.00 example 400</td>
<td>6.0</td>
<td>449.12</td>
</tr>
</tbody>
</table>

Source: CNAMTS

27http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000018213915&dateTexte=&oldAction=rchJ0
For generics, there is a special type of pharmacy remuneration that provides the same amount of money as remuneration for pharmacists as there is for delivering the original product (cf. section 3.4.2).

A flat fee of €0.53 (due only for reimbursable pharmaceuticals) is included in the price, and the patient pays this. This amount is also refunded by the health insurance funds, and by complementary health insurance.

The pharmacist remuneration also includes discounts/rebates from the supply chain as described in section 3.6.1.

3.5.3 Remuneration of other dispensaries

The fees paid to hospitals for handling the distribution of products authorised to be sold to outpatients have been regulated since October 2006: a total of €28 per line of delivery (a line of prescription can include, e.g., the delivery of three identical packs, with the fee always being €28). This fee is included in the price paid by the patient and the total amount is reimbursed on the same basis as for all reimbursable pharmaceuticals, by the Social Health Insurance (Assurance sociale, SHI) or Complementary Health Insurance Funds.

The remuneration for the few dispensing doctors is the same as for the pharmacists.

3.5.4 Value-added tax

The standard value-added tax (VAT) rate is 19.6% on most products and services in France, but the value-added tax (VAT) rate is 2.1% on reimbursable pharmaceuticals and 5.5% on non-reimbursable pharmaceuticals.

3.5.5 Other taxes

Fees for registration of market authorisation range from €674 to €25,400, and for parallel import authorisation from €674 to €9,150. The annual tax on pharmaceuticals or on parallel import pharmaceuticals ranges from €250 to €17,000. These taxes are paid to the French Health Products Safety Agency (AFSSAPS) by manufacturers or importers. An annual contribution (under Art. L 245-2 of the Social Security Code (CSS) on pharmaceutical manufacturers for promotional activities and also under Art. L245-6 of the Social Security Code (CSS) is funded from the manufacturers’ pharmaceuticals turnover.

3.6 Pricing related cost-containment measures

3.6.1 Discounts/ rebates

Discounts and rebates of the pharmacy purchasing prices (Prix d’achat des médicaments par les pharmaciens, PPP) are negotiated between the supplier and the pharmacist and are regulated.
For **reimbursable** pharmaceuticals the maximum level of rebates/discounts granted to pharmacists is fixed by regulations. The two latest regulations can be found in Art. L 138-9 of the Social Security Code (CSS): Pharmacists are not allowed to receive more than 2.5% discount for reimbursable products, with one exception for reimbursable generics as described hereafter.

For **reimbursable generics**, the regulation differs whether the pharmaceuticals are supplied through a wholesaler or directly from the manufacturer to the pharmacist as follows:

- For generics supplied by a wholesaler, the discount/rebate rate should be lower than 10.74%. In fact, this maximum limit was not well respected and the legislation was changed in 2008 (see below).

- For generics directly supplied by the manufacturer to the pharmacist, the Ministerial Order of 29 December 2005 limited the discounts/rebates given. They could not exceed 20% in 2006, and 15% in 2007 of the ex-factory price. If the advantages exceed this level the pharmacist must reduce the consumer price. These discounts are not allowed in 2008 anymore according to the Law (see below for details).

- **Nowadays**, as of 2008, according to the “Chatel” Law number 2008-3 of 3 January 2008:
  - the maximum discount/rebate for reimbursable generics is 17% of the ex-factory price whether or not it is directly supplied to the pharmacist
  - the pharmacist can also benefit from the wholesale margin.

As of 2008, for **reimbursable non-generics** from a generic group under the reference price “TFR”, the maximum discount/rebate is 17% of the reference price of the group (according to the “Chatel” Law number 2008-3 of 3 January 2008). A generic group, under the reference price system or not, is defined for all molecules of the same Anatomic Therapeutic Chemical (ATC) classification level 5, with the same dosage and the same packaging and it is composed of the original product which patent expired and its generics.

For **non-reimbursable** pharmaceuticals, the level of discount/rebate is not set. It can be either in cash or in additional packs of pharmaceuticals given free of charge. It is always possible to provide rebates/discounts to consumers (for information on claw-backs cf. section 4.6.4).

### 3.6.2 Margin cuts

At the time of writing, wholesale and pharmacy margins on reimbursable pharmaceuticals are regulated through a regressive mark up scheme (cf. section 3.5.1 and section 3.5.2). In 1999, 2003 and on 21 February 2004, pharmacy margins and wholesale margins were amended by regulations. The last modification was done in march 2008 for wholesalers (see section 3.5.1 for details).

---

28 [http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000017785995&dateTexte=]

29 [http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000017785995&dateTexte=]
### 3.6.3 Price freezes / Price cuts

The Minister of Social Affairs (MAS) at that time, Martine Aubry, had decided to submit all reimbursable pharmaceuticals for a new evaluation by Transparency Commission (1999). After this examination the usual procedure was to remove products from the positive list. However, in fact the Minister decided to reduce prices for pharmaceuticals with insufficient clinical benefit (SMR). After this, Minister Guigou followed this course of action and the Economic Committee for Health Care Products (CEPS) negotiated price cuts with the manufacturers.

Following this, Minister Douste Blazy introduced a new plan to reduce prices for patented products during the period 2004-2007. The plan focused on cost-containment in different areas: generics expenditure (rate of substitution); de-listing some products; offering greater pack sizes for chronic diseases; reducing hospital prices; decreasing prices of patented products, e.g. statins, proton pump inhibitors (PPI), antihypertensive products and generics; and decreasing the reference price (Tarif Forfaitaire de Responsabilité, TFR) level.

### 3.6.4 Price reviews

There was a 3-year plan to reduce prices. Table 3.7 shows the main price changes for the period January 2002 until March 2008 of pharmaceuticals ordered by decreasing turnover of the package.

<table>
<thead>
<tr>
<th>NAME</th>
<th>PUBLIC PRICE, VALUE-ADDED TAX (VAT) INCLUDED, in €</th>
<th>DIFFERENCE IN %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MARCH 2008</td>
<td>JANUARY 2002</td>
</tr>
<tr>
<td>PLAVIX 75MG CPR BT28</td>
<td>55.38</td>
<td>61.53</td>
</tr>
<tr>
<td>TAHOR 10MG CPR BT28</td>
<td>18.82</td>
<td>25.44</td>
</tr>
<tr>
<td>SERETIDE DISK500/50Y 60DOS</td>
<td>64.80</td>
<td>71.57</td>
</tr>
<tr>
<td>ARIMIDEX 1MG CPR BT28</td>
<td>127.70</td>
<td>149.51</td>
</tr>
<tr>
<td>PREVENAR INJ SRG0,5ML 1 A</td>
<td>57.34</td>
<td>63.45</td>
</tr>
<tr>
<td>NEULASTA 6MG INJ SRG0,6ML 1</td>
<td>1,216.16</td>
<td>1,308.25</td>
</tr>
<tr>
<td>TAHOR 20MG CPR BT28</td>
<td>37.72</td>
<td>44.21</td>
</tr>
<tr>
<td>GLIVEC 400MG CPR BT30</td>
<td>2,518.67</td>
<td>2,557.53</td>
</tr>
<tr>
<td>SYMBICORT TURB 400/12 60DOS 1DISP</td>
<td>54.48</td>
<td>57.78</td>
</tr>
<tr>
<td>INEXIUM 20MG CPR BT28</td>
<td>24.18</td>
<td>38.58</td>
</tr>
<tr>
<td>ELISOR 20MG CPR BT28</td>
<td>21.51</td>
<td>29.74</td>
</tr>
<tr>
<td>TAHOR 40MG CPR BT28</td>
<td>43.08</td>
<td>47.47</td>
</tr>
<tr>
<td>AMLOL 5MG GELU BT30</td>
<td>15.68</td>
<td>17.68</td>
</tr>
<tr>
<td>INEXIUM 40MG CPR BT28</td>
<td>33.67</td>
<td>49.19</td>
</tr>
<tr>
<td>COVERSYL 4MG CPR BT30</td>
<td>27.37</td>
<td>28.08</td>
</tr>
<tr>
<td>AVONEX 30MCG/0,5ML INJ SRG 4</td>
<td>940.87</td>
<td>1007.30</td>
</tr>
<tr>
<td>NAME</td>
<td>PUBLIC PRICE, VALUE-ADDED TAX (VAT) INCLUDED, in €</td>
<td>DIFFERENCE IN %</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td></td>
<td>MARCH 2008</td>
<td>JANUARY 2002</td>
</tr>
<tr>
<td>PYOSTACINE 500MG CPR BT16</td>
<td>24.90</td>
<td>25.05</td>
</tr>
<tr>
<td>NEORECORMON 30000 INJ SRG 4</td>
<td>1,089.33</td>
<td>1,208.46</td>
</tr>
<tr>
<td>ARICEPT 10MG CPR BT28</td>
<td>89.04</td>
<td>93.98</td>
</tr>
<tr>
<td>ELISOR 40MG CPR BT28</td>
<td>40.28</td>
<td>50.17</td>
</tr>
<tr>
<td>ENBREL 25MG INJ FL+SRG 4 +NEC</td>
<td>571.47</td>
<td>603.04</td>
</tr>
<tr>
<td>SINGULAR 10MG CPR PELL BT28</td>
<td>39.81</td>
<td>41.82</td>
</tr>
<tr>
<td>LAMISIL 250MG CPR BT28</td>
<td>50.71</td>
<td>58.92</td>
</tr>
<tr>
<td>HUMIRA 40MG INJ SRGO,8ML 2</td>
<td>1,137.06</td>
<td>1,175.38</td>
</tr>
<tr>
<td>VASTEN 20MG CPR BT28</td>
<td>21.51</td>
<td>29.74</td>
</tr>
<tr>
<td>COAPROVEL 300/12,5 CP PEL 28</td>
<td>29.78</td>
<td>31.40</td>
</tr>
<tr>
<td>MOPRAL 20MG GELU FP28</td>
<td>38.12</td>
<td>48.40</td>
</tr>
<tr>
<td>FOSAMAX 70MG CPR BT4</td>
<td>34.08</td>
<td>37.53</td>
</tr>
<tr>
<td>LANTUS 100UI/ML OPTISET 3ML 5</td>
<td>67.41</td>
<td>67.59</td>
</tr>
<tr>
<td>ACTONEL 35MG CPR BT4</td>
<td>34.08</td>
<td>37.53</td>
</tr>
<tr>
<td>TANAKAN 40MG CPR BT90</td>
<td>15.69</td>
<td>17.91</td>
</tr>
<tr>
<td>PARIET 20MG CPR BT28</td>
<td>37.68</td>
<td>40.64</td>
</tr>
<tr>
<td>ZYPREXA 10MG CPR BT28</td>
<td>116.85</td>
<td>117.04</td>
</tr>
<tr>
<td>VASTAREL 35MG LM CPR BT60</td>
<td>11.04</td>
<td>11.10</td>
</tr>
<tr>
<td>ART 50MG GELU BT30</td>
<td>19.60</td>
<td>19.71</td>
</tr>
<tr>
<td>PIASCLEDINE 300MG GELU BT15</td>
<td>7.86</td>
<td>7.90</td>
</tr>
<tr>
<td>SERETIDE DISK250/50Y 60DOS+DISP</td>
<td>48.74</td>
<td>52.41</td>
</tr>
<tr>
<td>ORELOX 100MG CPR BT10</td>
<td>11.72</td>
<td>13.77</td>
</tr>
<tr>
<td>XALATAN 0.005% COLLY FL2,5ML 1</td>
<td>17.57</td>
<td>18.77</td>
</tr>
<tr>
<td>GRANOCYTE 34 INJ FL+SRG 1</td>
<td>115.37</td>
<td>115.46</td>
</tr>
<tr>
<td>CRESTOR 10MG CPR BT28</td>
<td>27.37</td>
<td>27.45</td>
</tr>
<tr>
<td>AERIUS 5MG CPR BT30</td>
<td>11.46</td>
<td>13.03</td>
</tr>
<tr>
<td>CHONDROSULF 400MG GELU BT84</td>
<td>21.31</td>
<td>21.43</td>
</tr>
<tr>
<td>VASTEN 40MG CPR BT28</td>
<td>40.28</td>
<td>50.17</td>
</tr>
<tr>
<td>INIPOMP 20MG CPR BT28</td>
<td>21.50</td>
<td>22.96</td>
</tr>
<tr>
<td>CASODEX 50MG CPR BT30</td>
<td>140.66</td>
<td>140.85</td>
</tr>
<tr>
<td>ENBREL 50MG INJ FL+SRG 4 +NEC</td>
<td>1,117.30</td>
<td>1,129.77</td>
</tr>
<tr>
<td>INIPOMP 40MG CPR BT28</td>
<td>40.20</td>
<td>43.43</td>
</tr>
<tr>
<td>EZETROL 10MG CPR BT28</td>
<td>45.02</td>
<td>45.11</td>
</tr>
<tr>
<td>SUBUTEX 8MG CPR SUBLING BT7</td>
<td>22.18</td>
<td>24.25</td>
</tr>
</tbody>
</table>

bt = bottle, mg = milligram, ml = millilitre

Source: CNAMTS
4 Reimbursement

4.1 Organisation

The National Union of Health Insurance Funds (UNCAM) is in charge of setting the reimbursement rate after the assessment of medical service and the improvement of medical service by the Transparency Commission and cost-efficacy assessment, and simultaneously of the pricing procedure by the Economic Committee for Health Care Products (CEPS).

There is a positive list of reimbursable pharmaceuticals which is determined by the Ministry of Health after receiving technical advice from the Transparency Commission. Only pharmaceuticals that provide an improvement of medical service or savings in the cost of treatment are eligible for reimbursement.

The National Union of Health Insurance Funds (UNCAM) has been in charge of defining the reimbursement categories since 13 August 2004 (Art. L322-2 and L182-2 of the Social Security Code (CSS)). There are three reimbursement categories (cf. Table 4.1). The reimbursement rate is based on the HAS recommendation regarding SMR and the seriousness of the disease.

The composition of the Transparency Commission is defined in Art. R. 163-15 of the Social Security Code (CSS): 20 members with voting rights appointed by decision of the French National Authority for Health (HAS), consisting of one president (scientific), two vice-presidents, 17 members (scientific) and 6 substitute members.

In addition, there are eight members with consultative voice:

- four members of agencies or state representatives: director of social security department, director of health department, director of hospital department, director of French Health Products Safety Agency (AFSSAPS);
- four other members (three representatives of Health Insurance Funds, one for each main fund, and one representative of the pharmaceutical industry).


The Transparency Commission gives two kinds of appraisal for each new product or reappraisal, as detailed here.

- The level of actual clinical benefit (SMR) for each indication: medical value (severity of the disease, clinical effectiveness), interest for public health, target population. This level determines the rate of reimbursement. The SMR may be considered as major, moderate, weak or insufficient (cf. section 4.2.2). The normal rate is 65%. For products for the treatment of diseases without special gravity and homeopathic products the rate is 35% by law (Art. R322-1 of Social Security Code (CSS)).
• The level of improvement of clinical benefit (ASMR) or added value of a pharmaceutical within an indication. This level is determined in relation to relevant comparators, in particular the most recent product, the best-seller and the cheapest product. There is a four-level improvement of clinical benefit (ASMR) scale:
  o major (ASMR 1): new therapeutic area, reduction of mortality;
  o important (ASMR II): important improvement in therapeutic efficacy and/or with important reduction of side-effects;
  o moderate (ASMR III): modest improvement in therapeutic efficacy and/or with reduction of side-effects;
  o minor (ASMR IV): very minor improvement;
  o No improvement (ASMR V).

Comparisons are made with the products of the same Anatomic Therapeutic Chemical (Classification Anatomique, Thérapeutique, Chimique, ATC) classification code and also with products with the same therapeutic indications.

The Level of improvement of clinical benefit (ASMR) is directly linked with the price negotiation between the Economic Committee for Health Care Products (CEPS) and the pharmaceutical company. If there is no improvement in clinical benefit (ASMR), the pharmaceutical must be cheaper than therapeutic equivalents in order to be included in the positive list of reimbursable pharmaceuticals.

A special procedure is possible under the third paragraph of Art. R 163-2 of the Social Security Code (CSS), called “médicament d’exception”. In this case the prescription must be made with a special formulary and under control of the Health Insurance Funds’ managing doctors. A prescription guide (“Fiche d’Information Thérapeutique”, FIT) must be published at the same time as inclusion in the positive list and the price. The prescription guide (FIT) contains information on posology and duration of treatment, and also possible restrictions on prescribing or dispensing mentioned in the market authorisation. At the time of writing, only 35 products are on this list. They represent € 750 Mio. at ex-factory price level. The main therapeutic areas are erythropoietin, interferon beta, specific antirheumatic agents and growth hormone.

Since the introduction of the Law of 13 August 2004 the rate of reimbursement for each product has been determined by the National Union of Health Insurance Funds (UNCAM) (Art. L322-2 and L182-2 of the Social Security Code (CSS)).

The Minister of Health can decide that for some irreplaceable and costly products (e.g. treatments for cancer and HIV, as well as growth hormones), co-payment must be removed. This positive list is managed by the Ministry of Health under Art. R 322-2 of the Social Security Code (CSS).
4.2 Reimbursement schemes

4.2.1 Eligibility criteria

The French reimbursement scheme is both product and disease specific.

Product specific criteria

There is a positive list for the outpatient sector. Under Art. L 5126-4 of the Public Health Code (CSP) the Minister of Health can decide to authorise hospitals to dispense a list of products to outpatients. In this case the rate of co-payment is fixed by the National Union of Health Insurance Funds (UNCAM).30

Some products are dispensed by hospitals to outpatients without full market authorisation. They are regulated by Art. L 5121-12 and Art. R 5121-68 of the Public Health Code (CSP), with temporary utilisation authorisation (ATU) “nominative” for one patient or “cohorte” for a group of patients. No co-payment is required. This special authorisation is – like other authorisations - granted by the French Health Products Safety Agency (AFSSAPS). E.g., in 2004, 24,000 nominative temporary utilisation authorisations (ATU) were granted. At present nine products have been granted a temporary utilisation authorisation “ATU de cohorte”31.

Patient specific criteria

For certain groups of patients, expenses are fully reimbursed under Art. L 322-3 and L.324-1 of the Social Security Code (CSS) (Law of 13 August 2004), “Affection de longue durée or ALD” (Long-term illness) and Art. D 322-1, as described hereafter.

1. For patients with long-term illnesses from a specific list

Health insurance funds pay 100% of the expenses for a list of 30 chronic and costly diseases32. Some diseases which are not in the list of 30 diseases are also free of charge, when they constitute a progressive or disabling disorder, with a previous treatment period of longer than six months and are costly (e.g. degenerative macula), along with multiple diseases of more than six months’ duration.

Exemption from co-payment is only valid for treatment of long-term illness(es) (Affection de longue durée, ALD), whereas for other diseases normal reimbursement applies.

A special prescription form is needed with two zones (“ordonnancier bi-zone”: one for prescription in relation to long-term illness (ALD) at the top of formulary, and one for other diseases at the bottom.

31 http://agmed.sante.gouv.fr/htm/5/atu/indatu.htm
32 list defined in the Social Security Code art. D 322-1
When a patient suffers from certain conditions and the referring doctor wants her/him to be reimbursed fully for expenses related to those conditions, a special procedure is needed. A special protocol is required for this ("protocole de soins"), written on the basis of coordination between different actors necessary to cure the disease/condition, including a specialist, a nurse, or a "médecin traitant", who is a kind of “family doctor”, chosen by the policy-holder. This doctor sends the protocol to the medical department of the relevant health insurance fund to obtain an agreement.

The policy-holder (the patient) must sign the formulary approved by the medical service. In 2006, the expenditure under the long-term illness (ALD) category, covering nearly 8 million patients (14% of the general scheme policy-holders), amounted to 60% of reimbursable expenditure in 2004.

This represented a total of € 55.7 billion: € 17.5 billion for heart diseases, € 14 billion for cancers, € 10.2 billion for psychiatric affections and € 9 billion for diabetes. The first five long-term illnesses (ALD) in 2005 were malignant tumours (244,139 cases), diabetes (146,792), severe arterial hypertension (91,223), psychiatric diseases (84,880) and heart failure (67,287).

In 2006, near 9 million patients are in ALD.

The continuous growth of expenditure is due to the increase in population, in prevalence (e.g. diabetes, cancers, hepatitis), in life expectancy, and due to the expansion of the criteria for 100% reimbursement (e.g. fasting blood sugar level had gone down from 1.40 gr/l to 1.26 gr/l since the mid-1990s).

On average, patients (including the people in the “long-term illness” (ALD) category, covered at 100% rate) receive treatment funded at the 76 % level.

2. **For socially disadvantaged patients**

*Universal Health Insurance Coverage (CMU)*

Created by Law No. 99-641 of 27 July 1999 and introduced on 1 January 2000, the Universal Health Insurance Coverage (CMU) was an important development in France. This is a national unified system to allow people staying in France on a regular basis to access social security even if s/he is not covered by one of the national security systems. If the patient’s annual income level is below € 7,083, s/he is exempt from payment. It is also possible for these people to obtain complementary insurance without payment.

This insurance permits access, free of charge, to care from doctors and nurses, as well as paying for pharmaceuticals, hospital charges and normal charges per day in hospital (if they have the complementary assurance).

*State Medical Aid*

A foreigner who is not “in a regular situation” (i.e. without a residence permit) has the right to receive care under the State Medical Aid (Aide Médicale de l’Etat, AME) system. Different administrative conditions are required, e.g. the person must have stayed in France for three
months, and have sufficient income and proof of identity. In emergency situations, these obligations do not apply. The patient pays nothing under this scheme.

Table 4.1: France - Number of persons covered by the different health insurance schemes, 2000–2005

<table>
<thead>
<tr>
<th>No. of persons in Mio. covered by:</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base CMU</td>
<td>1.127</td>
<td>1.200</td>
<td>1.426</td>
<td>1.553</td>
<td>1.635</td>
<td>1.697</td>
</tr>
<tr>
<td>Complementary CMUC</td>
<td>4.977</td>
<td>4.600</td>
<td>4.468</td>
<td>4.650</td>
<td>4.664</td>
<td>4.735</td>
</tr>
<tr>
<td>AME</td>
<td>-</td>
<td>-</td>
<td>0.145</td>
<td>0.170</td>
<td>0.145</td>
<td>0.180</td>
</tr>
</tbody>
</table>

CMU = Universal Health Insurance Coverage, CMUC = Complementary Universal Health Insurance[^33]

Source: CNAMTS

4.2.2 Reimbursement categories and reimbursement rates

The following tables give an overview of the reimbursement categories and rates.

Table 4.2: France - Reimbursement of pharmaceuticals

<table>
<thead>
<tr>
<th>Reimbursement category by clinical benefit (SMR)</th>
<th>Reimbursement rate for serious disease</th>
<th>Reimbursement rate for non-serious disease</th>
<th>Characteristic of category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td>65%</td>
<td>35%</td>
<td>Normal rate determined by Minister of Health, UNCAM can modify it, +or - 5 points</td>
</tr>
<tr>
<td>Moderate</td>
<td>35%</td>
<td>35%</td>
<td>Normal rate determined by Minister of Health, UNCAM can modify it, +or - 5 points</td>
</tr>
<tr>
<td>Weak</td>
<td>35%</td>
<td>35%</td>
<td>Rate determined by Minister of Health, UNCAM can modify it, +or - 5 points</td>
</tr>
<tr>
<td>Insufficient</td>
<td>Not listed</td>
<td>Not listed</td>
<td>Not listed</td>
</tr>
</tbody>
</table>

SMR = clinical benefit, UNCAM = National Union of Health Insurance Funds

Source: Social Security Code (CSS)^[34]

[^33]: Patients with a revenue higher than the threshold for CMU can claim for a discount for registering to a complementary health insurance, the national health insurance fund (CNAMTS) is then in charge of paying the difference to the complementary health insurance

Table 4.3: France - Exceptions for reimbursement of pharmaceuticals

<table>
<thead>
<tr>
<th>Reimbursement category by clinical benefit (SMR)</th>
<th>Reimbursement</th>
<th>Characteristic of category</th>
</tr>
</thead>
<tbody>
<tr>
<td>For severe chronic diseases e.g. cancer</td>
<td>100% rate for serious disease (ALD)</td>
<td>Special list approved by Minister of Health</td>
</tr>
<tr>
<td>“Pending de-listing”</td>
<td>Listing at 15% rate Temporary rate for vein tonics determined by law This rate disappeared in January 2008.</td>
<td>Pending de-listing</td>
</tr>
<tr>
<td>List of costly pharmaceuticals for hospital use</td>
<td>80% or 100% for exceptions</td>
<td>Pharmaceuticals provided by hospitals but excluded of the service for fee payment system</td>
</tr>
</tbody>
</table>

ALD = rate for serious disease, SMR = clinical benefit

Source: CNAMTS

The law sets the rate, but now the National Union of Health Insurance Funds (UNCAM) is responsible for ensuring that the National Target for Health Insurance Expenditure (ONDAM) is not met, so it has the power to change the rate by +or- five points. E.g. 35% can become 30% or 40%.

Figure 4.1: France - Development of pharmaceuticals in Reimbursement Code

Source: LEEM/CNAMTS
### Table 4.4: France - Average reimbursement rates 1995, 2000–2006

<table>
<thead>
<tr>
<th>Real rate of reimbursement for pharmaceuticals</th>
<th>1995</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate</td>
<td>70.60</td>
<td>73.58</td>
<td>73.91</td>
<td>74.76</td>
<td>74.93</td>
<td>75.35</td>
<td>75.10</td>
<td>76.20</td>
</tr>
</tbody>
</table>

*Source:* CNAMTS, LEEM

### 4.2.3 Reimbursement lists

There is a positive list of reimbursable pharmaceuticals (Art. L 162-17 of the Social Security Code (CSS) for the outpatient sector. The list mentions only reimbursable therapeutic indications and comes under the responsibility of the Minister of Health after receiving technical advice from the Transparency Commission, a body of the French National Authority for Health (HAS).\(^{35}\)

The positive list is updated on a day-to-day basis by official bulletin. For the Health Insurance Funds the positive list\(^{36}\) is updated every week, like a database.

Inclusion of a pharmaceutical in the positive list is granted for five years, reassessed at each renewal (every five years). A product can also be reassessed if a major change appears in its profile. The Minister of Health can demand a total or partial reassessment of the positive list under Art. R 163-19 of Social Security Code (CSS).

After review, it is possible to de-list a product, to change the rate of reimbursement, or to modify the indications reimbursed once the actual conditions of use have been verified. The company can argue against the decision, and the case may go to court to challenge the decision once it has been published.

### 4.3 Reference price system

In France there is no reference price system like the one in Germany. However, for part of the generics sector there is a reference price system (Tarif Forfaitaire de Responsabilité, TFR), i.e. all pharmaceuticals in a generic group have the same level of reimbursement. The reimbursement limit called “tariff level” is often equal to the generic price and the reimbursement rate is often based on this tariff. If a product under this scheme is more expensive than the “tariff” (reference price), the patient must make up the difference.

A generic group is defined for all molecules of the same Anatomic Therapeutic Chemical (ATC) classification level 5, with the same dosage and the same packaging. The different reference price (TFR) level is modified by the Economic Committee for Health Care Products (CEPS).

---

\(^{35}\) [http://www.has-sante.fr/portail/upload/docs/application/pdf/ri_ct_2005_v.04-10-06.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/ri_ct_2005_v.04-10-06.pdf)

The list and the levels of tariffs are managed by the Economic Committee for Health Care Products (CEPS). The current policy of the Economic Committee for Health Care Products (CEPS) is to add a new group in the TFR list and the corresponding reference tariff each time a poor rate of substitution is observed for a generic group. This is combined with the actions of the National Union of Health Insurance Funds (UNCAM) upon generic substitution, through a convention with pharmacists.

The first list was implemented on 27 August 2003. In 2006, 116 generic groups were under TFR (about 60 molecules; source: “Les dépenses de médicaments remboursables en 2006”37, E&R 590, DREES, August 2007) and in 2007, generics groups under the reference price system represented around 12% of the generics market.

4.4 **Private pharmaceutical expenses**

Public pharmaceutical expenditure (PE) (social security and state or local funds) accounted for 69% of outpatient pharmaceutical expenditure (PE) in 2006. The remaining 31% from private expenditure included 19% of expenses for private health insurance and 12% out-of-pocket payments (OPP) (including cost-sharing and self-medication) of households (cf. section 2.2).

Private health insurance in France corresponds to complementary health insurance patients subscribe to on a (usually) voluntary basis. In 2006, 93% of the population was covered by complementary health insurance, including 4% covered by the free complementary universal health insurance coverage (CMUC) provided for people with low income.

4.4.1 **Direct payments**

There is free pricing for the over-the-counter (OTC) market, included the wholesaler and pharmacy level. The patient pays the full consumer price.

4.4.2 **Out-of-pocket payments**

4.4.2.1 **Fixed co-payments**

Since 1 January 2005, the patient pays for each consultation or visit to the doctor 1€ out of pocket (“participation forfaitaire” ou “forfait”). The maximum annual out-of-pocket payment (OPP) is € 50 for a consultation or visit with a doctor only.

As of 1 January 2008, the patient also pays a fixed co-payment of € 0.50 for each pack of pharmaceuticals (“franchises par boîte”) with an annual ceiling of € 50 and can be reimbursed by the complementary health insurances. If the complementary health insurances do so they pay more taxes so in practice they prefer not to. Children under 16 years old and the patients covered by the CMU are exempted of these out-of-pocket contributions.

4.4.2.2 Percentage co-payments

There is a percentage co-payment for medicines, which is the difference between the rate of reimbursement and 100% reimbursement, mostly reimbursed by complementary health insurances.

4.4.2.3 Deductibles

Not applicable

4.5 Reimbursement in the hospital sector

Hospitals can buy pharmaceuticals that are on a positive list registered by the Minister of Health under Art. L5123-2 of the Public Health Code (CSP)\(^38\).

Most pharmaceuticals dispensed in hospitals to inpatients are included in the daily rate, i.e. in the hospital's budget. However, for some highly innovative pharmaceuticals with regulated prices, hospitals can claim reimbursement from the Health Insurance Funds from 70 to 100% depending on the contract of good use with the Health Insurance, in addition to the daily rate.

For pharmaceuticals dispensed to outpatients, hospitals claim reimbursement directly from the Health Insurance Funds, including a margin, but this is gradually changing to a system with a fee-for-service payment per dispensation. Until recently, in private hospitals, inpatients had to pay for pharmaceuticals on top of the daily rate. At the time of writing, the system is the same in all hospitals, whether public or private.

4.6 Reimbursement related cost-containment measures

Since the Law of 14 August 2004, the National Union of Health Insurance Funds (UNCAM), after consultation with the body representing the complementary insurance and mutual funds (Union Nationale des Organismes Complémentaires d'Assurance Maladie, UNOCAM), can change the reimbursement rate for reimbursable pharmaceuticals up to five points above or below the current level. This means, in theory, if at the standard rate of 65% (60% to 70%) the National Target for Health Insurance Expenditure (ONDAM) seems to be not reachable, this power could be exercised to rectify the situation.

4.6.1 Major changes in reimbursement lists

In France several decisions were made after the global assessment beginning in 1999. Certain products have seen their reimbursement level revised to a lower level, often from 65% to 35%, and/or their prices have been reduced.

As a second step, three waves of assessment were put into operation:

1. **First wave**: 60 pharmaceuticals with insufficient clinical benefit (SMR) and not adapted with the updated therapeutic value lost their market authorisations and were removed from the positive list (Arrete of 24 September 2003).  

2. **Second wave**: 245 pharmaceuticals with non-prescription obligation have been examined. The Minister of Health decided to reimburse some of them (essentially products for vein disease) at 15% until 1 January 2007 instead of 35% and the remaining products were removed from the positive list. See HAS report 14 September 2005:

3. **Third wave**: Advice from the French National Authority for Health (HAS) on 18 October 2006, principally on Vasodilators. The Minister of Health decided that their rate is to be 15% until being delisted from reimbursement as of 1 January 2008. See HAS report 18 October 2006:

### 4.6.2 Introduction / review of reference price system

Since its introduction, no major changes have taken place. The products concerned are still only the generic groups. In the government plan to reduce deficit, all reference price (TFR) levels and the prices of original products (“princeps”) in a generic group were reduced by 15% at the beginning of 2006.

### 4.6.3 Introduction of new / other out-of-pocket payments

Since 1 January 2005, the patient pays for each consultation or visit to the doctor € 1 out-of-pocket (“participation forfaitaire” ou “forfait”). The maximum annual out-of-pocket payment (OPP) is € 50 for a consultation or visit with a doctor only.

As of 1 January 2008, the patient also pays a fixed co-payment of € 0.50 for each pack of pharmaceutical (“franchises par boite”) with an annual ceiling of € 50 and can be reimbursed by the complementary health insurances. If the complementary health insurances do so they pay more taxes so in practice they prefer not to. Children under 16 years old and the patients covered by the CMU are exempted of these out-of-pocket contributions.

---


40 [http://www.has-sante.fr/portail/upload/docs/application/pdf/recommandation_has.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/recommandation_has.pdf)

41 [http://www.has-sante.fr/portail/upload/docs/application/pdf/recommandation_de_la_has_3e_vague_de_reevaluation_pdf.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/recommandation_de_la_has_3e_vague_de_reevaluation_pdf.pdf)
4.6.4 Claw-backs

Art. 31 of the Finance Law of the Social Security System (LFSS) for 1999 introduced the principle of claw-backs (Art. L 138-10 of the Social Security Code (CSS)). This mechanism works like a tax.

In principle, all manufacturers of pharmaceuticals are concerned with the claw-back system. However, if they engage in an agreement with the Economic Committee for Health Care Products (CEPS), they are not concerned by the aforementioned taxes and pay a contribution, negotiated with the Economic Committee for Health Care Products (CEPS) under the processes described in the “accord cadre”.

By agreement, the Economic Committee for Health Care Products (CEPS) obtains the same amount of money as it is possible through the application of the law relating to claw-backs. If the turnover increases faster than a predetermined rate, the companies must pay part of this amount back to health insurance fund (between 55% and 68.1% for an excess between 1% and 8%).


Table 4.5: France - An overview of the growth of the amount paid by health insurance funds, 2000–2005

<table>
<thead>
<tr>
<th></th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate K in %</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Gross outpatient reimbursable turnover (A) in Mio. €</td>
<td>13,500</td>
<td>14,330</td>
<td>14,930</td>
<td>15,840</td>
<td>16,820</td>
<td>17,970</td>
</tr>
<tr>
<td>Annual growth in %</td>
<td>8.9</td>
<td>7.2</td>
<td>4.2</td>
<td>6.1</td>
<td>6.2</td>
<td>6.8</td>
</tr>
<tr>
<td>Excess/rate K in Mio. €</td>
<td>854</td>
<td>559</td>
<td>171</td>
<td>330</td>
<td>510</td>
<td>980</td>
</tr>
</tbody>
</table>

**Return of the system**

<table>
<thead>
<tr>
<th></th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fall of prices and de-listing in Mio. €</td>
<td>183</td>
<td>360</td>
<td>107</td>
<td>nc</td>
<td>24</td>
<td>160</td>
</tr>
<tr>
<td>Gross discount in Mio. €</td>
<td>411</td>
<td>262</td>
<td>204</td>
<td>254</td>
<td>381</td>
<td>501</td>
</tr>
<tr>
<td>Credit side used in Mio. €</td>
<td>137</td>
<td>79</td>
<td>75</td>
<td>64</td>
<td>32</td>
<td>93</td>
</tr>
<tr>
<td>**Net discount (B) in Mio. €</td>
<td>274</td>
<td>183</td>
<td>129</td>
<td>190</td>
<td>349</td>
<td>408</td>
</tr>
<tr>
<td>Theoretical claw-back amount (safeguard contribution) in Mio. €</td>
<td>442</td>
<td>370</td>
<td>100</td>
<td>150</td>
<td>296</td>
<td>523</td>
</tr>
<tr>
<td>Discount (B)/turnover (A) in %</td>
<td>2.03</td>
<td>1.27</td>
<td>0.86</td>
<td>1.20</td>
<td>2.07</td>
<td>2.27</td>
</tr>
<tr>
<td>Discount (B)/growth of turnover (A) in %</td>
<td>24.9</td>
<td>22.0</td>
<td>21.5</td>
<td>20.9</td>
<td>35.6</td>
<td>35.5</td>
</tr>
</tbody>
</table>

**Source:** HCAAM 2006 report on medicines

The claw-back system returns only a part of the excess of the previous turnover sum. However, Table 4.6 shows that the larger the excess, the more significant the return (in percentage).

4.6.5 Reimbursement reviews

Cf. section 4.6.1.
5  Rational use of pharmaceuticals

5.1  Impact of pharmaceutical budgets

In France there are no pharmaceutical budgets being applied for doctors or other health care providers, which means that there are no fixed prescribing budgets in terms of money available to health care professionals. Still, the prescription volume or prescribing habits of general practitioners (GPs) and specialists are monitored by health insurance funds, after consultation with the French National Authority for Health (HAS). Through this, doctors are encouraged to prescribe the most economically viable pharmaceutical (generics) from several therapeutically similar alternatives.

Since 2007, doctors have been able to see their prescription profile on the health insurance funds’ website.\(^{43}\)

The health insurance funds are starting to enter into agreements with hospitals. One objective is to change prescribing habits, e.g. by encouraging prescribers in hospitals to start new treatments using pharmaceuticals that are available in a community pharmacy, preferably generic ones if possible.

5.2  Prescription guidelines

The availability of computer-assisted prescription software (LAP: Logiciels d’Aide à la Prescription) certified by the French National Authority for Health (HAS) should foster generic substitution, particularly through the method of prescription according to International Nonproprietary Name (Dénomination Commune Internationale, INN).

Since the implementation of the Law of 13 August 2004, the French National Authority for Health (HAS) is required to develop guidelines for each of the 30 diseases fully reimbursed by health insurance fund. In 2008 all the guides were published. Now HAS begins to publish new guides in collaboration with INCA (French National Cancer Institute) on melanoma skin for example.

These guidelines are reviewed every three years. But during these period list of acts and deliveries are updated once a year.

Now for chronically diseases three months package are available.

The doctors have access to the web database of AFSSAPS or HAS or Health Insurance (AMeli website). To comply better with the convention, they receive also for following conventional action some paper guide like ‘Mes Molécules’. they also receive a professional letter from health insurance to follow the enforcement of the reform.

\(^{43}\) http://www.ameli.fr/
For special medicines "Médicaments d’exception" a guide is published on the official bulletin.

5.3 Information to patients / doctors

Advertising of pharmaceuticals is regulated by law (Art. L 5122-1 to L 5122-16 and Art. R.5122-1 to R. 5122-47 of the Public Health Code (CSP), in line with the European Commission (EC) Directive 2001/83/EC. Control of this legislation is carried out by the French Health Products Safety Agency (AFSSAPS) body, “Committee in charge of pharmaceuticals advertising control and recommendations on proper use”.

Direct advertising of over-the-counter (OTC) pharmaceuticals to patients is allowed by law (Art L. 5122-6 of the Public Health Code (CSP) as is advertising of vaccines or products reducing tobacco dependence. Advertising is prohibited for pharmaceuticals available on medical prescription only, for reimbursed products and also for products with advertising restrictions set out in the market authorisation. It is based on a system of prior vetting. When a non-prescription reimbursable product is de-listed, it is possible to advertise up to six months before de-listing, if an agreement is made between the Economic Committee for Health Care Products (CEPS) and the company, to preserve the financial interests of the health insurance fund during this period (Art. D 5172-7-1 of the Public Health Code (CSP).

Advertising of a pharmaceutical to people qualified to prescribe or supply is allowed. The French Health Products Safety Agency (AFSSAPS) must be notified of each advertisement during the eight days following the launch of the campaign. If a product has prescribing restrictions, advertising is only possible to people authorised to prescribe, including hospital pharmacists.

Advertising on the Internet of pharmaceuticals is allowed but according to general advertising regulation, i.e. it is prohibited for pharmaceuticals available on medical prescription only, for reimbursed products and also for products with advertising restrictions set out in the market authorisation. The French Health Products Safety Agency (AFSSAPS) and the pharmaceutical industry have signed a “charter of good conduct” on this. No sanctions exist.

Various measures are implemented in order to restrict or control the promotional spending of manufacturers:

- there are taxes on promotional expenditure; for 2005 the amount was € 227 million
- if an advertisement is forbidden, after transparency procedures, the Economic Committee for Health Care Products (CEPS) can charge the company a penalty of a maximum of 10% of the sales of the product concerned;
- a Charter on medical sales representatives has been signed between the Economic Committee for Health Care Products (CEPS) and the Association of Pharmaceutical Industry (LEEM) (Art. L 167-17-8 of the Social Security Code (CSS); The number of sales representatives was about 23,000 in 200544.

in a global agreement between the Economic Committee for Health Care Products (CEPS) and the pharmaceutical industry it was decided to reduce the amount of contact between each company and doctors in various medical fields, e.g., statins, proton pump inhibitors (PPI), antibiotics (macrolides and fluoroquinolones), triptans and antiasthma combined;

samples must be claimed by doctors, as under the agreement between the Economic Committee for Health Care Products (CEPS) and the industry, sales representatives are not allowed to carry samples – doctors request them directly from the company.

Health insurance funds manage the means of informing patients on rational use of pharmaceuticals (e.g. the famous “Antibiotics are not automatic” campaign on the uses of antibiotics), on prevention (through the preventive fund campaign on flu vaccines), on promoting vaccinations for rubeola-mumps-roseola (rougeole-oreillons-rubéole, ROR) and on iatrogenic for elderly people.

There is no regulation on information to patients in the inpatient sector.

In mid-2003 the national health insurance fund (National Insurance Fund for Salaried Employees (CNAMTS) implemented sickness insurance representatives (DAM) to visit doctors and pharmacists and explain the setup of the health insurance fund’s risk management arrangements (cf. section 2.1.1.2).

The National health insurance fund also conducts risk management through its Health Insurance Medical Control Service at local level. Each local health insurance fund (CPAM, Caisse Primaire d’Assurance Maladie) has its own Health Insurance Medical Control Service department, made up of advisory practitioners - doctors, chemists, dentists - and administrative staff. This service helps and controls social insured and healthcare professionals45 The service:

- Advises social policyholders and healthcare professionals on medico-social regulations and on the correct use of treatment.
- Provides assistance to policyholders and healthcare professionals to improve the management of long-term diseases.
- Analyses and manages patients’ applications for benefits and the activity of healthcare professionals and establishments.
- Manages the successful implementation of regulations and medical practices.
- Leads studies.

In this framework, the National Health Insurance Fund (CNAMTS) targets 62,000 visits of advisory practitioners ‘médecins conseils’ to health professionels in 2008.

5.4 Pharmaco-economics

Pharmaco-economic studies are not required by law for including a product in the positive list. If a pharmaceutical company produces such a study, it is assessed by the Transparency Commission and the Economic Committee for Health Care Products (CEPS) on an individual basis.

Since 2008, HAS is in charge of conducting pharmaco economic studies according to LFSS 2008. A new commission, the Economic and Public Health Evaluation Commission (CEESP-Commission d’Evaluation Economique et de Santé Publique) was created and pharmaco-economic reevaluation of statins, ACE inhibitors, angiotensin II antagonist and PPI will begin as of last semester 2008. As a consequence, such reevaluations could be appreciated for inscription on positive list renewal of reimbursed medicines.

5.5 Generics

Generics are defined in the Public Health Code (Code de la Santé Publique, CSP) Art. L601-646.46

The French Health Products Safety Agency (AFSSAPS) is responsible for the list of generics called ‘le repertoire’.47 The list is organised by groups of pharmaceuticals defined by the original product and its generics. A generic group is defined for all molecules of the same Anatomic Therapeutic Chemical (ATC) classification level 5, with the same dosage and the same packaging and it is composed of the original product which patent expired and its generics. In 2006, the list of generics accounted for € 3.1 billion (1.5 for original products and € 1.6 billion for generics), about 17% of the reimbursable market (source: LEEM).

In 2004, three measures affected the possible growth of the generics market:

1. Art. 19 of the Finance Law of the Social Security System (LFSS) for 2004 provides that market authorisation for a generic pharmaceutical can be delivered before the expiry of the intellectual property rights attached to the reference specialty.

2. Art. 30 of the Law of 13 August 2004 modifies the definition of a generic under European legislation. This article specifies that “the various salts, esters, isomers, isomer mixtures, complexes or derivatives from the same active principal are considered to be the same active principal, unless they present significantly different properties in term of safety and efficacy”.

3. Decree of 18 February 2005 introduced Art. R. 5121-41-1 of the Public Health Code (CSP). Minor changes in market authorisation are considered to be the same as the original authorisation.

As a result of these changes, the generics market will be less dependent on the actions of innovative firms for delaying entrance to the market of any new generic, and the French Health

46 http://www.legifrance.gouv.fr/affichCodeArticle.do;jsessionid=8EA7A901AA7D305DDE1162F194F55E11.tpdjo10v_2?cidTexte=LEGITEXT000006072665&idArticle=LEGJARTI000006693765&dateTexte=20080722&categorieLien=id
47 http://afssaps.sante.fr/htm/5/generiq/indgen.htm
Products Safety Agency (AFSSAPS) has become responsible only for the evaluation of bioequivalence in the course of the market authorisation procedure.

Table 5.1: France - Development of the generics market in the outpatient sector, 2000–2007

<table>
<thead>
<tr>
<th>Generics market share</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume (no. of packs counted in %)</td>
<td>5.5</td>
<td>7.0</td>
<td>7.5</td>
<td>10.1</td>
<td>13.4</td>
<td>14.8</td>
<td>17.7</td>
<td>20.5</td>
</tr>
<tr>
<td>Value (in %)</td>
<td>3.0</td>
<td>3.7</td>
<td>4.0</td>
<td>6.0</td>
<td>7.2</td>
<td>8.3</td>
<td>9.6</td>
<td>11.2</td>
</tr>
</tbody>
</table>

Source: CNAMTS

5.5.1 Generic substitution

Generic substitution has been allowed in France since 11 June 1999 (Art. L. 5125-23 of the Public Health Code (CSP). The French Health Products Safety Agency (AFSSAPS) monitors the positive list of generic products and establishes groups which contain the original product and its generics. Within each group, substitution by a pharmacist is possible. Certain substances are not protected by licence but are not included in a group by the French Health Products Safety Agency (AFSSAPS), even though the law permits the creation of a group for these products, e.g. paracetamol or aspirin.

Generic substitution is voluntary; it is optional for pharmacists. Parallel imports are included in the generic substitution system. Pharmacies are allowed to substitute a generic for a brand name pharmaceutical (e.g. the original product) but the substitution must be cheaper for the health insurance funds. This is possible if the doctor has written the prescription with its International Nonproprietary Name (INN) or with its brand name.

Both doctor and patient may oppose generic substitution. Opposition to substitution has no direct consequences for doctors, patients or pharmacists. However, the patient may lose money in one particular instance: if there is a reference price (TFR) for reimbursement for a generic group and the pharmacy retail price (PRP) of the brand name pharmaceutical is higher than the reference price (TFR), then the patient must pay for the difference out of her/his own pocket.

There are certain indirect financial incentives in place:

- for doctors – if pharmaceutical expenditure (PE) grows too fast it will not be possible to increase consultation or visit fees;
- for pharmacists – if they don’t reach the recommended rate of substitution the Government will implement new reference rates and they will lose money.

Pharmacies are not allowed to substitute therapeutically (i.e. dispense a pharmaceutical with equal therapeutic benefits (analogous substitution). Pharmacies are allowed to substitute parallel imported pharmaceuticals.
Generic substitution is allowed on a voluntary basis. It is promoted through:

- a financial incentive to pharmacists (higher margin);
- an agreement between the UNCAM and the union of pharmacists to increase the rate of substitution;
- the non-exemption of initial payment of the patient to the pharmacist (the system of direct payment by the health insurance fund to the pharmacist known as “tiers-payant” and applied in most situations);
- and through television (TV) advertising campaigns intended for consumers.

### 5.5.2 Generic prescription

Physicians are not obliged by law to prescribe generics, but by agreement with health insurance funds they have an indirect interest in prescribing generics. Physicians have a stake in the increase of generic prescriptions because the rise in the price of a consultation or a visit depends on the evolution of pharmaceutical expenditure (PE) under the convention signed with the health insurance funds.

Physicians are encouraged by agreement (5 June 2002) to write prescriptions by International Non-proprietary Name (INN) by agreement. In the most recent study carried out by the mutual funds it appears that doctors prescribe by International Non-proprietary Name (INN) in the generics market at a rate of 12% (in terms of volume). The rate of generic prescription is growing significantly.

### 5.5.3 Generic promotion

Generics are promoted by the Government, health insurance funds, pharmacists and generics manufacturers to reduce public expenditure. By saving money through generic promotion, it is possible to reward real innovative pharmaceuticals with a good price. The method of promoting generics is by creating a financial incentive for pharmacists by substituting a brand name pharmaceutical with a generic.

The Government, health insurance funds, manufacturers and pharmacists run television (TV) advertising campaigns aimed at consumers. The health insurance funds promote the acceptance of generics on the back of the reimbursement forms sent to patients, and provide physicians with information about their own rate of generic prescription, as well as comparing this with other physicians in the same area. The health insurance funds have signed an agreement with pharmacists to increase the rate of substitution from 60% to 70% by the end of 2006 and this goal was almost achieved.

The pharmacist’s margin is the same in value for a generic pharmaceutical as for the brand name pharmaceutical, it is not a percentage of the ex-factory price. This provides an incentive
for the pharmacist, whereas at the same time the cost for the health insurance funds is lower, as
the reimbursement rate is based on the price of the generic pharmaceutical, which is signifi-
cantly lower than that of the equivalent brand name pharmaceutical. However, when the refer-
ence price (TFR) becomes applicable to a generic pharmaceutical class, there is no longer any
incentive for the pharmacist, whose margin will be based on a percentage of the generic’s ex-
factory price, which is 30-50% lower than that of the equivalent brand name pharmaceutical.

In hospitals the generic market has been developed. The health insurance funds try to convince
doctors to write the first prescription for patients leaving the hospital with a pharmaceutical from
the list of health care establishments.

5.6 Consumption monitoring

Each year a special declaration is requested from all pharmaceutical manufacturers. They must
declare for each pharmaceutical the volume and the financial value of sales in ambulatory care
and in hospitals (Art. L5121-17 and L. 5121-18 of the Public Health Code (CSP) and Art. L. 162-
17-5 of the Social Security Code (CSS).

Each year the national health insurance funds publish reimbursed data for each registered
pharmaceutical. The health insurance funds can monitor each individual patient’s consumption
of pharmaceuticals prescribed and reimbursed by each doctor.

On the website of CNAMTS49 patients have access to an account with reimbursement details
(service “mon compte ameli”). This system allows the prescriber to access the last 12 month
reimbursed expenses if the patient agrees so.

High prescribing doctors (compare to other prescribers) can be identified and monitored by
health insurances. For instance, health insurance can constrain the doctor’s prescriptions to a
‘health insurance prior agreement’ (“entente préalable”), according to Article 37 of the LFSS
2008. This agreement is the responsibility of the Health Insurance Medical Control Service of
the health insurance (see section 5.3).

49 www.ameli.fr
6 Current challenges and future developments

This chapter covers the most oppressing pharmaceutical challenges for the health care system and the future plans to meet these challenges.

6.1 Latest changes

Since the 2004 reform, the last LFSS (Finance Law of the Social Security System) improved the regulation of the system along with social efficiency:

- Replace the patient as the centre of the health care system: choice of a referring doctor “médecin traitant” to optimize reimbursement through financial incentives constraints
  - Set-up of the gatekeeper role of the physician
  - Prevention programs development: breast cancer screening, antibiotics and bacterial resistance, influenza …
  - New co-payments (see table below)
- Improvement of hospital and ambulatory care convergence
- Agreements between health insurance and health professions, mainly physicians and pharmacists, in order to improve the efficiency of expenses of medicines
  - Promotion of generics
  - Best use of pharmaceuticals: statins, antibiotics, PPI…
- Reinforcement of role of institutions for setting prices and expenses regulation (CEPS and “Comité d’alerte”)
- Other specific measures:
  - Marketing of bigger packs (volume) of pharmaceuticals promoted
Table 6.1: France – Changes in the pharmaceutical system, 2005–2008

<table>
<thead>
<tr>
<th>Year</th>
<th>Pricing</th>
<th>Reimbursement</th>
<th>Not attributable to Pricing or Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Price reviews</td>
<td>-</td>
<td>January: Fixed co-payment of € 1 per visit to the physician</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Before July: Choice of “médecin traitant” (new role of gatekeeper), 10% decrease of reimbursement level otherwise (for visits and medicines)</td>
</tr>
<tr>
<td>2006</td>
<td>Price reviews</td>
<td>Reevaluation second wave (first in 2003): reimbursement level reviewed to lower level (35% to 15%) until 31 December 2007 for a list of medicines, removed from reimb. list as of 1 March 2006 for the remaining evaluated</td>
<td>Generic agreements with pharmacists</td>
</tr>
<tr>
<td>2007</td>
<td>Price reviews</td>
<td>Reevaluation third wave: Reimbursement level reviewed to lower level:</td>
<td>Review of generic agreements with pharmacist</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>First alert of the surveillance committee (“comité d’alerte”)</td>
</tr>
<tr>
<td>2008</td>
<td>Wholesaler mark up margins review</td>
<td>15% rate disappears for medicines of the 2nd wave of reevaluation (see 2006 above)</td>
<td>Diabetis program for patients monitored by health insurance funds “Sophia (disease management program)”</td>
</tr>
<tr>
<td></td>
<td>Ongoing negotiations for a unique “accord cadre” agreement between the Economic Committee for Health Care Products (CEPS) and the Association of Pharmaceutical Industry (Les Entreprises du Médicament, LEEM)</td>
<td>H.A.S. in charge of pharmaco economics studies</td>
<td>Mid-2008: a list of OTC products to be in free access in pharmacies</td>
</tr>
<tr>
<td></td>
<td>January: Fixed co-payment per package : € 0.5 (“franchise”)</td>
<td></td>
<td>Source: CNAMTS</td>
</tr>
</tbody>
</table>
6.2 Current challenges

Considering that the pharmaceutical expenditure (PE) per inhabitant is higher in France than in other European countries, especially with prescriptions of pharmaceuticals in disagreement with the summary of product characteristics (SPC), the Law of 13 August 2004 provides for a reduction in pharmaceutical volumes through medical control of prescriptions, development of generic prescription and gradual implementation of a reference price (TFR) system.

6.3 Future developments

Currently different ways for sustaining the health insurance scheme are discussed and must be agreed on for the 2009 Finance law (LFSS) such as:

- Redefine the respective roles of obligatory and complementary insurance
- Identify best(s) way(s) for better sustainability of the health system: pricing for innovation, productivity of the research, access to health system for all on the whole territory?
- Define the roles of the new regional institutions “ARS” (Agence Régionale de Santé), with an objective of a better geographical organisation and coordination between ambulatory and hospital care
- Improve selection of new drug covered by the health insurance system: dynamic management of the flow of product covered by the system (going in, going out)
- Review management for public research connected with private sector and university
- Education and training of prescribers certification
- Development of guidance by the HAS: new approach for chronic diseases
- Enhance decisions transparency: faster publication of advices, publication of conflict of interests
- Development of a public database on medicines and product: administrative and economic
- Develop access to health data for researchers
- Improve prescribers involvement and motivation: set up one-to-one agreement with financial incentives between the prescriber and the health insurance funds
- Improve economic regulation by the CEPS through administrative processes for medicine harmonisation between ambulatory care and hospital care
- Expand control of industry sales representatives activities: process certification by the HAS of the pharmaceutical industry communication to health professionals set up (through sales representatives)
- Development of services offered by authorities to prescribers and patients
- Development of information letters by AFSSAPS, HAS, CNAMTS with new professionals targeted: pharmacists, nurses, hospitals ....
- Enhance information provided to prescribers on their prescriptions habits (‘prescription profiles’ developed by the health insurance according to conventional agreements), give them access to consumption data at patient level ‘Mon compte Ameli-historique des remboursements’ (based on reimbursement, expenses taken in charge by health insurance)

- Certification of computer-assisted prescription softwares (“Logiciels d’Aide à la Prescription”, LAP) by HAS

- Development of electronic pharmaceutical record: data collected by the pharmacists (“Dossier Pharmaceutique”, DP)

- Development of electronic health record “Dossier Medical Partagé”, DMP

- In the future sectors to be explored in greater depth: ways to control the prices of new pharmaceuticals, especially temporary utilisation authorisation (ATU) products and orphan pharmaceuticals
7 Appendixes

7.1 Further reading

High Committee for the Future of Social Security (Haut comité sur l’avenir de l’assurance maladie, HCAAM) report on pharmaceuticals

Reports of Court of Account

Reports of Economic Committee for Health Care Products (CEPS)

Reports of the French National Authority for Health (HAS)

Reports of the National Insurance Fund for Salaried Employees (CNAMTS)

Reports of Commission des Comptes de la Sécurité Sociale

7.2 Web links

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Name</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDIC FRANCE</td>
<td>Information portal on pharmaceuticals</td>
<td><a href="http://www.medicfrance.sante.gouv.fr/">http://www.medicfrance.sante.gouv.fr/</a></td>
</tr>
<tr>
<td>LIR</td>
<td>International Research Laboratories</td>
<td><a href="http://www.lir.asso.fr/">http://www.lir.asso.fr/</a></td>
</tr>
</tbody>
</table>
| LEEM         | Association of Pharmaceutical Industry   | http://www.leem.org/htm/accueil/accueil.as
<p>| GEMME        | Generic Producers Association             | <a href="http://www.presstvnews.fr/moxygeniere/gemmepresent.htm">http://www.presstvnews.fr/moxygeniere/gemmepresent.htm</a> |
| FSPF         | Federation of Pharmacists in France       | <a href="http://www.fspf.fr/">http://www.fspf.fr/</a>                      |
| UNPF         | National Union of Pharmacists of France   | <a href="http://www.unpf.org/">http://www.unpf.org/</a>                     |
| USPO         | Union of Pharmacists                      | <a href="http://www.uspo.fr/article.php3?id_article=1">http://www.uspo.fr/article.php3?id_article=1</a> |
| CSMF         | Confederation of French Medical Unions   | <a href="http://www.csmf.org/">http://www.csmf.org/</a>                     |
| MG FRANCE    | French Federation of General Practitioners| <a href="http://www.mgfrance.org/">http://www.mgfrance.org/</a>                 |
| SML          | Union of Self-employed Doctors            | <a href="http://www.lesml.org/">http://www.lesml.org/</a>                    |
| FMF          | Federation of Doctors in France           | <a href="http://www.fmfpro.com/plan.php3">http://www.fmfpro.com/plan.php3</a>          |
| UCCMSF       | Doctors Association                       | <a href="http://www.uccms-idf.com/">http://www.uccms-idf.com/</a>                |
| CNAMTS       | National Insurance Fund for Salaried Employees| <a href="http://www.ameli.fr/">http://www.ameli.fr/</a>                   |
| MSA          | Agricultural Mutual Insurance Fund (for farmers and farm employees) | <a href="http://www.msa.fr/">http://www.msa.fr/</a> |</p>
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Name</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSI</td>
<td>National Insurance Fund for Self-employed Workers</td>
<td><a href="http://www.le-rsi.fr/">http://www.le-rsi.fr/</a></td>
</tr>
<tr>
<td>CEPS</td>
<td>Economic Committee for Health Care Products</td>
<td><a href="http://www.sante.gouv.fr/ceps/">http://www.sante.gouv.fr/ceps/</a></td>
</tr>
<tr>
<td>HCAAM</td>
<td>High Committee for the Future of Social Security</td>
<td><a href="http://www.securite-sociale.fr/institutions/hcaam/hcaam.htm">http://www.securite-sociale.fr/institutions/hcaam/hcaam.htm</a></td>
</tr>
<tr>
<td>HAS</td>
<td>French National Authority for Health</td>
<td><a href="http://www.anaes.fr/anaes/anaespar">http://www.anaes.fr/anaes/anaespar</a> metametre.nsf/HomePage?ReadForm</td>
</tr>
<tr>
<td>COMMISSION DE LA TRANSPARENCE</td>
<td>Transparency Commission</td>
<td><a href="http://www.has-sante.fr/has/transparence/index.htm">http://www.has-sante.fr/has/transparence/index.htm</a></td>
</tr>
<tr>
<td>IRDES</td>
<td>Research Institute for health economy</td>
<td><a href="http://www.irdes.fr/">http://www.irdes.fr/</a></td>
</tr>
<tr>
<td>AFIPA</td>
<td>French Association of Self-medication Industry</td>
<td><a href="http://www.afipa.org/">http://www.afipa.org/</a></td>
</tr>
<tr>
<td>MINEFE</td>
<td>Ministry of Economy, Finance and Employment</td>
<td><a href="http://www.minefe.gouv.fr/">http://www.minefe.gouv.fr/</a></td>
</tr>
<tr>
<td>LEGIFRANCE</td>
<td>Government official site for law and regulations</td>
<td><a href="http://www.legifrance.gouv.fr/">http://www.legifrance.gouv.fr/</a></td>
</tr>
<tr>
<td>MAS</td>
<td>Ministry of Social Affairs</td>
<td><a href="http://www.sante.gouv.fr/assurance_maladie/index.htm">http://www.sante.gouv.fr/assurance_maladie/index.htm</a></td>
</tr>
<tr>
<td>DREES</td>
<td>Research Department for Ministry of Social Affairs (MAS)</td>
<td><a href="http://www.sante.gouv.fr/drees/index.htm">http://www.sante.gouv.fr/drees/index.htm</a></td>
</tr>
<tr>
<td>COUR DES COMPTES</td>
<td>Court of Accounts</td>
<td><a href="http://www.ccomptes.fr">http://www.ccomptes.fr</a></td>
</tr>
</tbody>
</table>

### 7.3 Authors

Authors of PPRI Pharma profile France (as of 2007):

Eric VAN GANSE, MD, PhD - Pharmacoepidemiology Unit, Université Lyon 1, Lyon, France

Geneviève CHAMBA, PharmD, PhD, Faculty of Pharmacy, Université Lyon 1, Lyon, France

Genevieve BRUET, Pharmacoepidemiology Unit, Université Lyon 1, Lyon, France

Valérie BECQUART, Association of Pharmaceutical Industry (LEEM)
Catherine STAMM, Hospital Pharmacist, CHU Lyon

Christian MARTY and Sophie LOPES, CNAMTS, Paris

_2008 update_

Sophie LOPES, health economist at the Strategy, Research and Statistics Directorate (DSES), CNAMTS, Paris

Christian MARTY, advisor at the Healthcare Organisation and Management Directorate (DDGOS)